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ABSTRACT 
 
 
Members of the ATP-binding cassette (ABC) family of drug transporter proteins 
translocate various endogenous and exogenous substrates across intra- and extracellular 
membranes.  Two specific ABC transporters, the multidrug resistance 1/P-glycoprotein 
(MDR1/P-gp) and the multidrug resistance protein 2 (MRP2), serve as major hepatic 
transporters that mediate the biliary excretion of various organic anions and cations along 
with glutathione-, glucuronate-, or sulfate-conjugates of several drug substrates.  
However, very little is known about the expression of these transporters in the early 
infant and childhood ages of human development.  We, therefore, characterized the 
ontogeny of these transporters by measuring their gene and protein expression.  
Furthermore, we also characterized the ontogeny of four nuclear receptors through 
measurement of their gene expression.  Nuclear receptors belong to a highly conserved 
gene superfamily of transcriptional factors that regulate the expression of their target 
genes, many of which include members of the ABC transporters.  We identified four 
main nuclear receptors that have been associated with the modulation of  gene expression 
of MDR1/P-gp and MRP2 to include pregnane X receptor (PXR), constitutive androstane 
receptor (CAR), farnesoid X receptor (FXR), and hepatic nuclear factor 4α (HNF4α).  
Our study revealed lower gene expression of MDR1/P-gp and MRP2 in the early infant 
period of development.  We also identified a lower protein expression of MRP2 in the 
early infant period.  For the nuclear receptors, we found significantly lower expression 
levels for PXR and FXR in the early periods of development.   Positive correlations were 
established between the nuclear receptors PXR and FXR to the ABC transporters 
MDR1/P-gp and MRP2.  HNF4α, which has been described as a master regulator of 
other nuclear receptors, was determined to be positively correlated with PXR and CAR.  
 
Due to the various challenges associated with conducting scientific research in 
newborns, infants and children and obtaining tissue samples in this population, we 
wished to establish the ontogeny of the human equivalent of the ABC transporters and 
nuclear receptors in a rat model.  As such, we determined the ontogeny of Mdr1a/1b, 
Mrp2, Pxr, Car, Fxr, and Hnf4α from rat liver samples in seven different postnatal ages 
in order to compliment our human results with more selected spacing of age and sample 
numbers in our rat samples.  Similar to our human pediatric liver findings, rat liver 
Mdr1a/1b and Mrp2 gene expression appeared limited in the first week of life and 
increased thereafter.  The same findings were true for the rat P-gp and Mrp2 protein 
samples.  The rat nuclear receptors Pxr, Car, and Fxr all exhibited a positive correlation 
with both Mdr1a/1b and Mrp2 gene expression.  Furthermore, Hnf4α was also positively 
correlated with all three nuclear receptors. 
 
In a subsequent experiment, we aimed to explore the functional consequences in 
changes in drug transporter expression on the pharmacokinetics of their drug substrates.  
Ceftriaxone, a third generation cephalosporin antibiotic frequently used in pediatric 
pharmacotherapy, was selected as our model compound.  The pharmacokinetics of a 
single intravenous dose of ceftriaxone was compared between wild-type (WT) Wistar rats 
as compared to a mutant strain of Mrp2-deficient (TR-) rats.  We chose the use of TR- 
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rats as a surrogate animal to represent the immaturity of Mrp2 early on in development as 
was evident from our rat and human liver samples model.  Using the TR- rat model, we 
reported significantly longer elimination half-life (t1/2) (p < 0.05), undetectable amounts 
of drug in the feces (p < 0.05), and an increase in the urinary excretion of unchanged drug 
(p < 0.001) in the TR- as compared to the WT rats. 
 
In summary, these results demonstrate that the hepatic ABC transporters 
MDR1/P-gp and MRP2 are differentially expressed during childhood maturation and 
suggest that the observed reduced expression of MRP2 in human liver in early infancy 
may result in clinically significant differences in the disposition of medications used in 
pediatric pharmacotherapy. 
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CHAPTER 1.   INTRODUCTION  
 
 
Developmental Pharmacology 
 
Developmental pharmacology represents an area of pediatric research that translates 
our current knowledge of normal physiologic growth and development into age 
appropriate clinical pharmacotherapy.  This relatively new field within pharmacologic 
research grew out of necessity in the late 20th century with an emergence of reports 
describing a lack of drug efficacy and/or drug related toxicity in the neonatal and 
pediatric population.  Standard classical approaches of using dosing guidelines based on 
adult doses scaled for weight or body surface area (BSA) may lead to toxicity in the 
pediatric population.  This is well documented in the case of “gray baby syndrome” 
where infants given adult doses of chloramphenicol scaled by body weight died of 
chloramphenicol toxicity due to the inability of their liver enzymes to detoxify the drug.  
Sadly, the newborns who received chloramphenicol exhibited a myriad of physical signs 
and symptoms including an ashen appearance (thus termed “gray baby syndrome”), 
vomiting, respiratory distress, refusal to feed, periods of cyanosis, abdominal distention, 
cadiovascular collapse, and eventually death [1].  Other examples of drugs exhibiting an 
increase or decreased efficacy, or worse, ineffective drug therapy and/or severe toxicity 
in the pediatric population include zidovudine, acetaminophen, caffeine, digoxin, 
aminoglycosides, carbamazapine, valproic acid, and phenytoin [2, 3].   
 
The Food and Drug Administration Modernization Act of 1997 (FDAMA) 
emphasizes the critical need for clinical studies and improved guidelines of drug use in 
pediatrics.  In particular, FDAMA allows the regulatory agency to not only mandate 
labeling changes for a list of approved drugs for which additional pediatric information 
may produce health benefits but also, when appropriate, to request manufacturers to 
design and conduct pediatric clinical trials on new drug applications.  This mandate has 
led to the creation of a Pediatric Priority List, consisting of drugs with off-labeled usage 
in pediatrics.  The list has been updated annually to include new drug entities and remove 
drugs updated with new pediatric labeling.  An example of the drugs on the Pediatric 
Priority List is shown in Table 1-1.  A more recent law passed by Congress in 2002, 
termed the Best Pharmaceuticals for Children Act (BPCA), encourages drug 
manufacturers or sponsors to conduct pediatric studies for either on-patent or off-patent 
drugs.  In return, the manufacturer may obtain six months of additional market 
exclusivity for their patented drug.  Should the manufacturer decline the request from the 
Food and Drug Administration regarding further pediatric studies, especially in the case 
for off-patent drugs, the act then enables the Foundation for the National Institute of 
Health (FNIH) to fund such studies. 
 
In order to achieve safe and effective use of drugs in pediatrics, there must be an 
understanding of the impact of the normal growth and development process (ontogeny) 
on the pharmacokinetic (PK) and pharmacodynamic (PD) properties of medications.  The 
fundamental pharmacokinetic processes include absorption, distribution, metabolism, and 
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Table 1-1. Example of Drugs Currently Listed on the Pediatric Priority List. 
 
 
Product Name Indication 
  
 
Albuterol Asthma 
Alprazolam Anxiety 
Ampicillin/sulbactam Antibiotic 
Benazepril Hypertension 
Bumetanide Diuresis 
Cephalexin Antibiotic 
Diclofenac Anti-inflammatory 
Dopamine Increase cardiac output 
Efavirenz HIV infection 
Furosemide Diuresis 
Lithium Bi-polar disorder 
Methylphenidate Attention-deficient hyperactivity disorder 
Metoclopramide Prokinetic 
Omeprazole Gastro-esophageal reflux 
Oxycodone Pain 
Paroxetine Depression. Obsessive-compulsive disorder 
Pravastatin Hypercholesterolemia 
Rosiglitazone Type II diabetes 
Valproate Mania. Migraine prevention. Seizures. 
Venlafaxine Depression. Generalized anxiety disorder. 
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elimination (ADME) while pharmacodynamics can be described by the relationship of 
the concentration at the effect site and the observed beneficial or toxic effects.   
 
Absorptive processes that can change with maturation include factors such as 
gastric pH, gastric emptying and motility, intestinal length, epidermal thickness, and even 
skeletal-muscle blood flow.  Distribution of drugs into a physiologic space relies heavily 
on the body composition of an individual.  Since distribution of small drug molecules in 
the body is mainly driven by diffusion, their physicochemical properties including 
molecular weight, ionization, and permeability are crucial determinants of their volume 
of distribution.  For example, infants in general have relatively larger extracellular (40% 
total body weight) and total-body water spaces (80%) along with higher water to lipid 
ratio in their adipose stores as compared to adults (20% extracellular/50% total-body 
water).  Thus, the apparent volumes of distribution for hydrophilic drugs in newborns 
will be larger then those of adults.  Another factor that can alter the volume of 
distribution is protein binding. Newborns have frequently reduced plasma protein binding 
as compared to adults.  This results in a higher fraction of unbound drug in the plasma of 
newborns.  Reduced protein binding in newborns may be due to an overall decrease in 
total plasma protein concentration, higher plasma free fatty acids concentration and 
unconjugated bilirubin resulting in competitive displacement of acidic drugs from 
albumin binding sites, and potential competitive binding from residual compounds passed 
from the mother prior to birth [4].  
 
Drug metabolizing enzymes (DMEs) are subdivided into two groups – Phase I and 
Phase II.  Phase I enzymes are primarily responsible for the biotransformation of a wide 
array of endogenous and exogenous compounds.  Phase II enzymes generally inactivate 
or detoxify xenobiotics through conjugation with small molecules such as glutathione, 
uridine diphosphate glucuronic acid (UDPGA), or sulfates.  More recently, elimination of 
xenobiotics and their metabolites by uptake and export transporters has been referred to 
as Phase III of the elimination process.  Pediatric drug metabolism differs greatly from 
adults due to a differential maturation in drug-metabolizing enzymes prior to and after 
birth.  The ontogeny of Phase I enzymes, comprised of those in the cytochrome P450 
(CYP450) family, has been well characterized for several members including CYP3A, 
CYP2C, CYP2D, CYP2E, and CYP1A (Figure 1-1).  The CYP3A enzymes account for 
approximately 30% of total hepatic CYP450 content [5] and contributes to the oxidative 
metabolism of approximately 50% of marketed drugs [6].  CYP3A7 has been established 
as the predominant enzyme of the CYP3A family in newborns.  An ontogenic switch 
from CYP3A7 to CYP3A4 occurs shortly after birth whereby 3A7 rapidly declines in the 
first weeks of life and 3A4 increases throughout the postnatal period [7, 8].  Though 
CYP2D6 protein can be detected in the neonate liver, its activity (as assessed by 
dextromethorphan metabolism) remains low (< 1% of adults) and only increases to 
approximately 20% of adult enzymatic activity after 28 days of life [9, 10].  The CYP2C 
subfamily accounts for approximately 20% of the total adult CYP450 content and 
metabolism of current drugs on the market [5, 11].  The two predominant isoforms of the 
CYP2C family include CYP2C9 and CYP2C19.  At birth, CYP2C9 expression is 
comparable to that of adults but CYP2C19 expression requires an additional five months 
of postnatal development before reaching maximal values [12].  Expression and function  
 3
  
 
Figure 1-1. Ontogeny of CYP450 Family of Drug Metabolizing Enzymes. 
Source: Reprinted from Seminars in Fetal and Neonatal Medicine, Volume 10, Blake M. 
J. et al., ‘Ontogeny of drug metabolizing enzymes in the neonate’, 123-38, 2005, with 
permission from Elsevier.
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of both CYP2E1 and CYP1A1 increase with postnatal age.  Furthermore, the large  
variability observed for CYP2E1 and CYP1A1 expression appears to be dependent upon 
xenobiotic induction or inhibition along exposure to various environmental factors [13].  
Knowledge regarding the development of Phase II metabolizing enzymes including 
glucuronosyltransferases (UGT), sulfotransferases (SULT), glutathione-S-transferases 
(GST), and N-acetyltransferases (NAT) is incomplete.  However, preliminary reports 
suggest that while many of the Phase II enzymes are expressed early in development 
others exhibit tissue-specific ontogenic expression [14].  Many of the Phase III 
transporters belong to the ATP-binding cassette family (ABC) as well as the solute 
carrier family (SLC).  These transporters can facilitate the cellular uptake or extrusion of 
various endogenous and exogenous compounds.  Expression of these transporters appears 
organ and tissue specific, however, very little is known regarding the ontogeny of these 
transporters.  A more detailed discussion of these various drug transporters will be 
provided in the subsequently sections.  
 
Renal elimination of xenobiotics depends on glomerular filtration rate, active 
secretion and reabsorption through renal tubular transporters, as well as passive 
reabsorption.  At birth, glomerular filtration rate (GFR) increases dramatically with 
postnatal age and approaches adult values as early as 6 months of age for a full term 
infant [15, 16].  Renal secretion and reabsorption depend on various transporters 
including those belonging to the ATP-binding cassette (ABC) family, organic 
anion/cation transporters (OATs/OCTs), and the peptide co-transporter PEPT2, a member 
of the SLC15 family [17].  Unfortunately, little information exists regarding the 
maturation of these transporters in the renal tubule.  Ongoing research has already 
improved the identification and characterization of these renal transporters, but 
ultimately, studies into their developmental processes will help clarify our understanding 
of pediatric renal drug elimination. 
 
Similar to renal transporters, ontogeny of pharmacodynamic (PD) processes has 
received little attention in the literature.  The phamacodynamic response is a result of the 
interaction between the drug molecule and receptors and its downstream molecular 
consequences including changes in ion channels, second messenger systems, and 
signaling pathways results in a complex process.  Much of the Food and Drug 
Administration (FDA) guidance for conducting pediatric studies [18] is based upon an 
underlying assumption that drug action, concentration-response rate, and clinical 
outcomes in pediatric pharmacotherapy are comparable to adults.  However, as in the case 
of tacrolimus, the imprecision resulting from the use of a priori PK parameters from 
adults in a pediatric model demonstrates the limitations of these basic assumptions [19].  
Pharmacodynamic parameters including receptor concentration, affinity, and intrinsic 
activity may very well demonstrate age-associated differences in their effect.  Dose-
response discrepancies due to age-associated effects have been documented for warfarin 
[20], cyclosporine [21], sotalol [22] and midazolam [23]. 
 
While advances in developmental pharmacology during the past decade have 
certainly improved our understanding of pediatric physiology, there remains a gap in 
incorporating these age-associated changes into clinical pharmacotherapy.  Furthermore, 
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the maturation of key PK parameters including several Phase II drug metabolizing 
enzymes, Phase III transporters, and various PD parameters such as cellular receptors and 
signaling pathways still warrant further investigation. 
 
 
Hepatic Drug Disposition 
 
For most small molecule drugs, overall drug elimination occurs through two main 
components; namely, clearance via the renal route (CLR) and clearance via hepatic 
metabolism and transport (CLH).  As described previously, efficient and effective 
biotransformation and inactivation/detoxification of xenobiotics starts with Phase I and 
Phase II drug metabolizing enzymes.  Furthermore, elimination of xenobiotics and their 
metabolites through liver transporters into the bile is part of Phase III of the elimination 
process.  Because of the overlap in their substrate specificity, tissue distribution, and gene 
regulation between several drug metabolizing enzymes and transporters, Phase I/II and 
Phase III processes appear to work synergistically to decrease the oral bioavailability and 
increase the renal and biliary excretion of xenobiotics [24-26].  
 
It is well established that genetic polymorphisms and environmental factors can 
influence an individual’s expression and function of DMEs [27].  However, recent studies 
suggest that developmental changes in DMEs can also contribute to the variability 
observed for drug metabolism.  Detailed reviews in recent years on the development of 
Phase I and Phase II enzymes provide detailed insight into the differences observed 
between pediatric versus adult pharmacokinetics [3, 13-15, 28].  However, knowledge 
regarding drug transporter ontogeny is currently very limited.   
 
 
Hepatic Transporters 
 
As mentioned previously, Phase III transporters are comprised of those belonging in 
the ATP-binding cassette family (ABC) as well as the solute carrier family (SLC).  
Hepatic transporters are an essential component in the overall hepatic clearance and 
hepatobiliary elimination.  A multitude of hepatic transporters align both the apical 
(canalicular) and basolateral (sinusoidal) membranes of the hepatocyte (Figure 1-2).  
Transporters expressed in the basolateral membrane mediate the uptake of various 
organic anions and cations from the blood into the liver [29, 30].  Transporters in the 
canalicular membrane belong to the ABC family and mediate the transport of various 
organic anions and cations along with glutathione-, glucuronate-, or sulfate-conjugates of 
several drug substrates into the bile.  The focus of the current dissertation will focus on 
these apical transporters, specifically MDR1/P-gp (ABCB1) and MRP2 (ABCB2), as 
these are the main transporters which mediate the hepatobiliary elimination of a number 
of drug substrates (for simplicity, only the common transporter name will be used).  
However, the role of the uptake transporters in hepatic clearance should not be 
undermined and will be considered in future investigations. 
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Figure 1-2. Select Drug Transporters in Human Hepatocytes. 
MDR1/P-gp (ABCB1), multidrug resistance 1; MRP1 (ABCC1), multidrug resistance 
protein 1; MRP2 (ABCC2), multidrug resistance protein 2; MRP3  (ABCC3), multidrug 
resistance protein 3; OATP-E (SLCO4A1), organic anion transport polypeptide E; OCT1 
(SLC22A1), organic cation transporter 1; NTCP (SLC10A1), sodium taurocholate 
cotransporting polypeptide; OATP-B (SLCO2B1), organic anion transport polypeptide B; 
OAT2 (SCL22A7), organic anion transporter 2; Na+, sodium.  
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The ATP-binding cassette (ABC) superfamily of transporters consists of seven 
subfamilies of highly conserved proteins that mediate the unidirectional transport of 
various endogenous as well as exogenous compounds.  MDR1/P-gp was originally  
identified in 1976 as a 170 kDa cell surface glycoprotein displaying drug resistance 
properties in cancer cells [31].  Several years later, this multidrug transporter was found  
to actively extrude a large number of diverse compounds including natural products, 
hydrophobic amphipathic compounds, as well as cytotoxic drugs used in anticancer 
therapy [32].  In humans, P-gp is encoded by the MDR1 gene.  However, in rodents, P-gp 
is the product of two gene isoforms – Mdr1a and Mdr1b.  The sequence homology along 
with domain organization of all ABC transporters is well conserved.  ABC transporters 
characteristically have 12 transmembrane regions organized into two membrane spanning 
domains (MSDs).  Each MSD is associated with a nucleotide-binding domain (NBD) 
located on the cytoplasmic side of the membrane (Figure 1-3 and Figure 1-4) [33, 34].  
The α-helices of the MSDs form pore-like structures through which different substrates 
on the intracellular side can be extruded across the lipid bilayer.  Conformational changes 
within MSDs due to substrate binding are believed to induce an open or closed state of 
these transporters [35, 36].  Adenosine triphosphate (ATP) associated with the binding 
domains provides the energy required for active transport of substrates against the 
concentration gradient.  P-gp is highly expressed in several organs including the brush 
border membrane of enterocytes, the canalicular surface of hepatocytes, the apical 
surface of proximal tubules in the kidney, and the endothelial cells of the blood brain 
barrier [37, 38].  Localization of P-gp is particularly conducive for its role in extruding 
xenobiotics or toxins thereby protecting against cellular toxicity. 
 
MRP2, initially named the canalicular multi-specific organic anion transporter 
(cMOAT), was discovered as the defective transporter in the human Dubin-Johnson 
syndrome as well as the naturally occurring mutant strains of the Eisai 
hyperbilirubinemic (EHBR) and transport deficient (TR-) rats.  MRP2 is encoded by the 
ABCC2 gene and has a molecular weight of approximately 190 kDa. Unlike P-gp, the 
structure of MRP2 contains an extra membrane spanning domain at the NH2-termus 
which terminates in the extracytosolic region (Figure 1-3B) [39, 40].  MRP2 is highly 
expressed in the gut, liver, and kidney and shares many of the same substrates as P-gp 
[41].  MRP2 plays an important role in the hepatobiliary transport of a range of 
conjugated and unconjugated anionic compounds as well as bile acids and bilirubin.  Due 
to its function in the transport of a gamut of glucuronidated drug substrates, it is no 
surprise that MRP2 co-localizes with various Phase II metabolizing enzymes.  
Furthermore, MRP2 mediated transport of xenobiotics often depends on co-transport with 
reduced glutathione (GSH) [42]. 
 
Similar to Phase I and Phase II enzymes, hepatic transporters are subject to genetic 
polymorphisms drug-induced inhibition, and drug- and disease-induced alterations of 
expression levels. These interactions and alterations may profoundly influence the fate of 
drugs.  An example of a transporter based drug-drug interaction involves fexofenadine 
and erythromycin.  Fexofenadine, a histamine 1 (H1)-selective antagonist, does not 
undergo significant biotransformation in humans with 95% of the dose excreted in either 
urine or bile [43].  Co-administration of fexofenadine with erythromycin increases the  
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Figure 1-3. Predicted Secondary Structures of P-gp (A) and MRP2 (B). 
MSD, membrane spanning domain; NBD, nucleotide binding domain; CL, cytoplasmic 
loop.  Source: Reprinted from Toxicology and Applied Pharmacology, Volume 204, 
Leslie E.M. et al., ‘Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, 
and BCRP (ABCG2) in tissue defense’, 216-237, 2005, with permission from Elsevier.
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Figure 1-4. Graphic Representation of P-gp. 
Represented is a single P-gp transporter with two membrane spanning domains (MSDs) 
each associated with six transmembrane regions.  Associated with each MSD is a 
nucleotide binding domain (NBD).  Grey arrows trace the path of substrates.
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steady state plasma levels of fexofenadine by 109% [44].  A study using isolated perfused 
rat liver with fexofenadine and erythromycin concludes that erythromycin inhibits the 
biliary excretion of fexofenadine thus contributing to its increase in plasma concentration 
[45].  Another documented transporter based drug-drug interaction occurs between 
digoxin and quinidine.  Quinidine inhibits biliary excretion of digoxin as mediated 
through P-gp by as much as 42% [46]. 
 
As more transporter associated drug interactions emerge in the literature, 
knowledge about the changes which occur during transporter development become 
increasingly important.  While the ontogeny of hepatic Phase I and Phase II clearance 
mechanisms have been well documented [16], little is known regarding the development 
of drug transporters and its potential impact on the pharmacokinetic and 
pharmacodynamic profile of medications.  One of the most dramatic examples of P-gp 
associated drug toxicity involves the use of loperamide, a potent opioid agent often used 
as an antidiarrheal agent.  Central nervous system (CNS) toxicity by loperamide results in 
respiratory depression; however, at the recommended doses, loperamide entry into the 
CNS is prevented by P-gp at the blood brain barrier.  Despite its apparent safety, case 
reports of loperamide induced respiratory depression in infants have been described in the 
literature [47, 48] and loperamide is contraindicated for children under two year of age.  
The question whether this is directly due to a lower expression of P-gp in children 
younger than two years remains to be answered.  Another example of a potential 
transporter related drug toxicity involves ceftriaxone and MRP2.  Ceftriaxone is a third 
generation cephalosporin antibiotics often used in the pediatric population to treat lower 
respiratory infections or acute otitis media.  Approximately 33% of the drug is eliminated 
unchanged in the bile through MRP2 [49, 50].  There are several clinical reports of 
ceftriaxone related biliary sludge or pseudolithiasis in the pediatric population [51, 52].  
This is secondary to the high concentration of ceftriaxone in the liver which forms an 
insoluble salt with calcium in the bile [53].  In fact, in cases where high doses of 
ceftriaxone are given, the risk of ceftriaxone induced cholestasis drastically increases 
[54]. Little is known regarding the development of MRP2 in the human liver.  Immature 
or lower expression of MRP2 in the liver in the early years of life may lead to an 
accumulation of ceftriaxone in the hepatocyte and thus, increase the risk of cholestasis.  
However, further studies are needed in order to elucidate the development of MRP2 in 
human pediatric livers and confirm the mechanisms underlying these adverse events 
caused by administration of ceftriaxone in children. 
 
 
Nuclear Receptors – PXR, CAR, FXR, HNF4α 
 
Like the ABC transporters, nuclear receptors (NRs) also comprise a highly 
conserved superfamily of genes.  Instead of encoding for drug transporters though, NRs 
transcribe into various transcriptional factors which regulate the expression of their target 
genes.  Functionally, constitutive and inducible NRs can modulate the expression of 
several phase I and II drug metabolizing enzymes as well as drug transporters when 
activated by endogenous and exogenous compounds including hormones and drug 
molecules [55, 56].  The well conserved structure of NRs includes a variable modulator 
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domain known as an activation function 1 (AF1) at the N-terminus followed by the DNA-
binding domain (DBD) containing two well conserved zinc fingers specific to NRs.  
DBD links the receptor to the promoter regions of its target genes termed either hormone 
response elements (HREs) or xenobiotic response elements (XREs).  Located on the C-
terminus are the ligand binding domain (LBD) as well the activation function 2 (AF2).  
As the name suggests, the LBD serves as the binding site for specific ligands.  Upon 
ligand binding, LBD undergoes a conformational change resulting in a transcriptionally 
active state prepared for recruitment of coactivators by activation function 2 (AF2) 
(Figure 1-5).  Based on their classification, NRs can either bind to their target sequences 
as a homodimer, heterodimer, or a monomer [56]. 
 
Nuclear receptors that target expression of genes which encode for P-gp and MRP2 
include the pregnane X receptor (PXR/NR1I2), the constitutive androstane receptor 
(CAR/NR1I3), the farnesoid  X receptor (FXR/NR1H4), and the hepatic nuclear factor 
4α (HNF4α) [57].  PXR and CAR have been implicated in the coordinate induction of 
phase I and II drug metabolizing enzymes and drug transporters [58].  FXR is a bile acid 
receptor responsible for the regulation of bile acid synthesis and enterohepatic 
recirculation [59].  HNF4α, a constitutively expressed NR, is crucial for liver 
development and differentiation and also appears to be a key regulator for various drug 
disposition gene expression [57]. 
 
 
Central Hypothesis and Specific Aims 
 
Hepatic drug clearance involves a concerted process involving drug metabolizing 
enzymes and drug transporters.  While much effort has been placed in understanding the 
ontogeny of drug metabolizing enzymes (Phase I and Phase II), there remains a void in 
our knowledge into the developmental process of drug transporters.  Hepatic export 
transporters of particular relevance for the elimination of clinically used drugs into the 
bile include MDR1/P-gp and MRP2.  We hypothesized that in pediatric livers, MDR1/P-
gp and MRP2 mRNA and protein expression would be significantly lower early in 
development (infancy) as compared to older ages (childhood and adulthood).  We 
hypothesized that these expression differences would have functional consequences that 
affect the in vivo pharmacokinetics of drugs which are substrates for these transporters. 
Because nuclear receptors including PXR, CAR, FXR, and HNF4α regulate the 
expression of MDR1 and MRP2, we hypothesized these nuclear receptor would be 
correlated with MDR1/P-gp and MRP2 expression and would also exhibit significantly 
lower mRNA expression in the early period of development.   
 
In specific aim 1 (Chapter 2), we characterized the ontogeny of hepatic drug 
transporters (MDR1/P-gp and MRP2) and nuclear receptors (PXR, CAR, FXR, and 
HNF4α in human pediatric liver samples.  We hypothesized that there would be lower 
hepatic drug transporter and nuclear receptor expression in the early infant period of 
development as compared to the older childhood ages.   
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Figure 1-5. Basic Structure of Nuclear Receptors. 
AF, activation function; DBD, DNA-binding domain; LBD, ligand binding domain.   
Reprinted with permission.  Wang, H. and E.L. LeCluyse.  “Role of orphan nuclear receptors in the regulation of drug-metabolising 
enzymes.”  Clin Pharmacokinet, 2003. 42(15): p. 1331-57.
 
In specific aim 2 (Chapter 3), we defined the ontogeny of hepatic drug transporters 
(Mdr1a, Mdr1b, and Mrp2) and nuclear receptors (Pxr, Car, Fxr, and Hnf4α) in Sprague-
Dawley rats in order to better pinpoint the age-specific changes in drug transporter 
expression hypothesized to occur in newborns and infants.  We investigated seven 
predetermined ages ranging from newborn to adults. We hypothesized that in these rats, 
there would be lower hepatic drug transporters and nuclear receptors expression early on 
during development as compared to the older ages. 
 
In specific aim 3 (Chapter 4), we explored the functional consequences and 
potential clinical implications of low transporter expression as postulated for newborns 
and infants and determined the effect of MRP2 deficiency on the in vivo 
pharmacokinetics of ceftriaxone, a Mrp2 substrate frequently used in pediatric 
pharmacotherapy, in a animal model using wild-type (WT) and Mrp2-deficient (TR-) 
rats.  We hypothesized that in the TR- rats, there would be a decrease in overall clearance 
(CLT), longer half-life (t1/2), higher area under the curve (AUC), and no biliary excretion 
(as determined by fecal drug recovery) as compared to the WT rats. 
 14
CHAPTER 2.   AGE-ASSOCIATED EXPRESSION OF HEPATIC ABC DRUG 
TRANSPORTERS AND NUCLEAR RECEPTORS IN HUMAN PEDIATRIC 
LIVER 
 
 
Introduction 
 
As discussed in Chapter 1, maturational changes in the physiology of organs 
involved in drug disposition can translate into profound differences observed in the 
pharmacokinetic and pharmacodynamic properties of various therapeutic agents often 
used in pediatric pharmacotherapy.  Developmental changes in the gastrointestinal tract, 
protein binding, drug metabolizing enzymes and drug transporters, and renal filtration are 
just some examples of factors that can impact the absorption, distribution, metabolism, 
and elimination (ADME) of drug molecules. 
 
The 1962 Kefauver-Harris amendments to the Food, Drug, and Cosmetics Act 
(FD&C) mandated that prior to approval marketed drugs must have documented safety 
and efficacy for use in humans.  However, pharmaceutical manufacturers often excluded 
children during the clinical trials and labeled the use of such medications only in adults 
with a disclaimer that safety and efficacy had not been established in children.  
Unfortunately, deviations in the pharmacokinetic parameters of therapeutic agents often 
used as “off-label” medications in pediatric pharmacotherapy can lead to adverse risks 
such as underdosing, overdosing, and unanticipated adverse events.  Dr. Harry Shirkey, 
then chair of the American Academy of Pediatrics Committee on Drugs in 1968, called 
attention to the exclusion of children and coined the term “therapeutic orphan” [60]. 
 
The complexity of physiological and pathophysiological processes which occur 
during the maturational process certainly adds a level of intricacy in studies involving the 
pediatric population.  The ontogeny of drug metabolizing enzymes and its contribution 
towards differences seen in pediatric drug biotransformation have been widely studied 
and reviewed [2, 3, 13, 61].  However, studies regarding the ontogeny of drug 
transporters are still limited.  What is known about the development of drug transporters 
stem from mainly rodent models [61-65].  Furthermore, the animal data mostly focus on 
the development of transporters in rodent brain, intestine, and kidney rather than liver 
tissue [61-63, 66].  There are, however, a few human studies on the ontogeny of drug 
transporters using post-mortem fetal samples [65, 67]. Currently, there are no published 
studies on the development of human hepatic drug transporters during the early postnatal 
into childhood ages. 
 
In general, most of the rodent studies suggest the presence of an age associated 
difference of transporter expression in various organs.  One of the most studied ABC 
transporters thus far, due to its ability to extrude drug substrates from cells, has been 
MDR1/P-gp.  Using a mouse model, Watchko [66] has reported limited intestinal and 
brain P-gp expression at birth (approximately 20% of adult), but levels dramatically 
increased throughout maturation [66].  On the flipside, hepatic and renal levels of P-gp in 
neonatal mice and throughout development have been quantified at levels comparable to 
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adult values [62].  In rats, Mdr1a and Mdr1b have also been reported to exhibit age 
associated differences at the mRNA and protein level in the liver, kidney, brain, heart and 
lung.  Specifically, transcript level ranged two to three folds lower at birth with levels 
increasing throughout maturation reaching maximal expression by postnatal day 60 [63].  
In early gestation (14-20 weeks) human fetal liver samples, van Kalken [65] was able to 
detect P-gp in the bile canaliculi by as early as 14 weeks through immunostaining.  No 
differences in staining intensity were observed between the specimens between the 
different fetal stages [65]. 
 
Another transporter in the ABC family with a significant role in hepatobiliary 
elimination of drug substrates is MRP2.  Ontogeny of Mrp2 mRNA expression has been 
explored in rodent models in recent years.  The results showed an approximate 50% 
increase in Mrp2 mRNA expression from birth through postnatal day 60 in the rat liver 
and kidney [63].  A separate study quantified the postnatal Mrp2 protein expression level 
in rat liver and concluded that at birth, neonate expression of Mrp2 approximated 70% of 
adult values, eventually surpassed the adult values within a month and a half, but 
eventually leveled to adult values within three months [68].  One study noted 
approximately 50% Mrp2 mRNA expression in one day old rat liver tissue which 
dramatically increased to adult levels in one to three weeks.  In the same samples, Mrp2 
protein levels approximated < 20 % of adults in the same group and increased gradually 
to those of adults values by 4 weeks of age [69].  For humans, Chen [67] showed a 50% 
lower MRP2 genetic expression level in ten human fetal liver samples between 14 – 20 
weeks as compare to adult liver samples [67].   
 
Nuclear receptors comprise transcriptional factors which regulate the expression of 
their target genes, several of which include drug metabolizing enzymes and drug 
transporters [70].  While limited reports of drug transporter ontogeny in animal models 
and human fetal liver samples are slowly surfacing, studies on the developmental 
expression of nuclear receptors are even scarcer.  PXR and CAR, both members of the 
NR1 family, are key regulators of genes involved in the metabolism and transport of most 
xenobiotics, including CYP3A and P-gp/MDR1 [58, 71, 72].  Another member of the 
NR1 family, FXR, is a bile acid sensor responsible for regulation of bile acid synthesis 
and enterohepatic recirculation [56, 73, 74].  All three nuclear receptors are associated 
with the regulation of MRP2 [72].  Another hepatic nuclear receptor, HNF4α, has been 
reported as a master regulator of  PXR [75] and CAR [76].  Vyhlidal [77], in a recent 
study with limited postmortem pediatric liver samples (n = 20; ages 4 days to 18 years), 
reported an age association in mRNA expression of PXR and CAR.  Furthermore, 
expression of PXR and CAR were limited in the first six months of life, but increased 
several folds after six months of age.  In the same study, the authors also quantified 
mRNA expression of HNF4α and showed that HNF4α was positively correlated with 
both PXR and CAR expression [77]. 
 
While the rodent studies provide us some information regarding the developmental 
expression of ABC transporters Mdr1/P-gp and Mrp2 in various tissues, studies regarding 
the development of such transporters and nuclear receptors in humans are rare due to the 
limited availability of human pediatric liver samples.  While the small number of 
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available reports based on human fetal and postmortem pediatric liver samples provide a 
glimpse into some pre- and postnatal transporter and nuclear receptor expression, there 
still lacks information during other phases of development such as during the newborn 
and early childhood periods. 
 
The overall object of the present study was to characterize the ontogeny of ABC 
transporters MDR1 and MRP2 as well as the nuclear receptors PXR, CAR, FXR, and 
HNF4α in human pediatric liver samples ranging from immediately after birth through 
twelve years of age.  Potential age associated changes in hepatobiliary transporters 
MDR1/P-gp and MRP2 may result in significant differences in the biliary clearance of 
medications used in pediatric pharmacotherapy.  Knowledge regarding the impact of such 
changes in transporter expression during the newborn and early childhood periods on 
pharmacokinetic parameters can contribute to more age-appropriate dosing and thus 
better safety and efficacy profiles especially for those medications with limited or no 
labeling for pediatric use. 
 
 
Materials and Methods 
 
 
Sample Acquisition 
 
Human pediatric liver tissues were acquired from two main sources – St. Jude 
Children’s Research Hospital (SJCRH, Memphis, TN) and the Medical College of 
Wisconsin (MCW, Milwaukee, WI).  The samples from SJCRH (n = 62) originated from 
the Liver Tissue Procurement and Distribution System (University of Pittsburgh, 
Pittsburgh, PA, funded by National Institutes of Health Contract N01-DK-9-2310) and 
from the Cooperative Human Tissue Network (University of Alabama, Birmingham, AL, 
funded by the National Cancer Institute).  Samples from MCW (n = 67) originated from 
the Brain and Tissue Bank for Developmental Disorders, University of Baltimore and 
University of Miami (National Institute of Child Health and Human Development 
contract N01-DK-8-3284).  All samples were collected from donors less than twelve 
years of age.  The SJCRH samples were obtained from living donors either through 
biopsy or within one hour of cross-clamping in the case of organ donors.  Harvested 
tissue was immediately flash frozen in transplant solution.  Demographic information on 
the donor population and health status is provided in Table 2-1.  All SJCRH samples 
were used for the mRNA expression analysis and a subset (n = 45) was used for the 
protein analysis.  The unmatched sample numbers between mRNA and protein 
expression analysis was due to limitations in tissue availability.   
 
Unlike the SJCRH samples, all MCW samples were obtained from deceased 
donors.  Due to the degradation of mRNA during the period from time of death to sample 
collection – defined as the post-mortem interval (PMI), the postmortem samples were 
only used for P-gp and MRP2 protein analysis.  The postmortem samples from donors 
with disease processes that could potentially involve liver damage were excluded from  
 17
Table 2-1. Donor Demographics for Human Pediatric Liver Samples Provided by St. 
Jude Children’s Research Hospital (SJCRH). 
 
 
 
 
 
N 
 
Age (yrs) 
Mean ± SD 
 
 
Age Group   
A (< 0.7 Y) 9 0.53±0.18 
B (0.7 - < 3 Y) 19 1.69±0.45 
C (3 - < 6 Y) 12 3.83±0.83 
D (6 - 12 Y) 22 8.38±2.04 
 
Gender   
M 29  
F 22  
Unknown 11  
 
Race   
Caucasian 35  
Black 7  
Others 6  
Unknown 14  
 
Disease status   
Normal 36  
Cirrhosis 10  
Fibrosis 10  
Acute Hepatitis 4  
Necrosis 2  
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the study.  Demographic information for the MCW samples is provided in Table 2-2.  
The combined patient demographics from SJCRH and MCW samples used for protein 
expression analysis are presented in Error! Reference source not found.. 
 
 
Total RNA Isolation and cDNA Synthesis 
 
Total ribonucleic acid (RNA) from human pediatric liver samples were isolated 
using the phenol:chloroform method using the Promega RNAgents® Total RNA 
Isolation Kit (Promega, Madison WI) according to the manufacturer’s protocol.  Frozen 
liver tissue (approximately 0.3 g) was added to 600 µL of denaturing solution per 
protocol and subjected to homogenization until no fragments of tissue were visible.  To 
each homogenate, 60 µL of 2M sodium acetate (pH 4.0) was added and mixed 
thoroughly by inversion.  600 µL of phenol:chloroform:isoamyl alcohol was 
subsequently added to the mixture and mixed by inversion 3 – 5 times followed by 
vigorously shaking for 10 seconds.  The samples were then placed on ice for 15 minutes.  
Thereafter, the samples were subjected to centrifugation at 10,000 g for 20 minutes at 4ºC 
in order to separate the organic and aqueous phases.  The top aqueous phase containing 
RNA was carefully separated to a fresh vial and an equal volume of isopropanol was 
added to each sample.  RNA was pelleted by centrifugation at 10,000 g for 15 minutes 
after alcohol precipitation for 30 minutes at -20ºC.  The RNA pellet was then washed 
with 1.0 mL of 75% ethanol, and the pellet was again collected by centrifugation at 
10,000 g for 15 minutes.  The pellet was air-dried after discarding the supernatant and 
evaporating the residual ethanol.  Each RNA pellet was re-dissolved in 10 – 50 µL of 
nuclease-free water depending on the pellet size.  RNA concentrations were determined 
by measuring its ultraviolet absorbance (A) at 260 nm and 280 nm, respectively, whereby 
1 absorbance unit (A260) = 40 µg of RNA/mL.  The purity of the RNA isolate was 
estimated by comparing the ratio for A260/A280.  Samples were considered to be pure 
total RNA with only minor protein contamination if the ratio of A260/A280 calculated 
between 1.7 and 2.0.  Integrity of each RNA sample was assessed by agarose gel 
electrophoresis comparison of intact ribosomal 18S and 28S bands.  The ratio between 
28S to 18S band intensity ranged approximately around 2 – an indication that no gross 
degradation of RNA had occurred during processing.  Only samples with high purity and 
integrity were further processed for first strand cDNA synthesis. 
 
First strand complementary deoxyribonucleic acid (cDNA) synthesis was 
performed by using the Superscript III kit (Invitrogen, Carlsbad, CA) on an Eppendorf® 
Mastercycler™ (Westbury, NY).  Oligo deoxyribose thymidine (dT) was used as the 
primer for messenger RNA (mRNA) first-strand synthesis.  An aliquot totaling 1 µg of 
total RNA was mixed with 1 µL of 10 mM deoxyribonucleotide triphosphate (dNTP) mix 
and 1 µL of 0.5 µg/µL Oligo(dT)12-18.  The total mixture was then brought to 10 µL 
with the addition of diethylpyrocarbonate-treated (DEPC) water.  The mixture was 
incubated at 65ºC for 5 minutes on a heating block, then immediately placed on ice for at 
least one minute.  A mixture of 2 µL of 10x reverse transcriptase (RT) buffer, 4 µL of 25 
mM magnesium chloride (MgCl2), 2 µL of 0.1 M dithiothreitol (DTT), 1 µL of 
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Table 2-2. Donor Demographics for Human Pediatric Liver Samples Provided by 
Medical College of Wisconsin (MCW).  
 
  
  Age (yrs) PMI (hrs) 
  
 N 
 
Mean ± SD 
 
Mean ± SD 
 
 
Age Group   
A (<0.7 Y) 42 0.23±0.15 18.1±8.21 
B (0.7 - < 3 Y) 3 2.24±0.32 15.67±2.31 
C (3 - < 6 Y) 7 4.22±0.96 17.43±9.43 
D (6 - 12 Y) 16 9.20±1.55 21±7.28 
    
Gender    
M 45   
F 23   
Unknown 0   
    
Race    
Caucasian 42   
Black 22   
Others 3   
Unknown 1   
    
PMI, post-mortem interval. 
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Table 2-3. Combined Patient Demographics for Human Pediatric Liver Samples for 
Protein Analysis. 
 
  
 
 
N 
 
 
Age (Yrs) 
Mean ± SD 
 
 
Age Group   
A (< 0.7 yrs) 48 0.26 ± 0.17 
B (0.7 - < 3Y) 15 1.64 ± 0.60 
C (3 - < 6 Y) 16 3.97 ± 0.89 
D (6 - 12Y) 33 9.0 ± 1.75 
 
Donor Status   
living 45   
deceased 67   
 
Gender    
M 61   
F 44   
UNK 7   
 
Race    
Caucasian 68   
Black 28   
Others 7   
Unknown 9   
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RNAseOUT™ recombinant RNase inhibitor, and 1 µL of SuperScript™ III reverse 
transcriptase were added to each reaction vial.  The mixture was then incubated for 50ºC 
for 50 minutes and the reaction was terminated by increasing the temperature to 85ºC for 
5 minutes.  The residual RNA was removed by adding 1 µL of RNAse H and incubating 
at 37ºC for 20 minutes.  cDNA was stored at -20ºC until real-time RT-PCR was 
performed. 
 
 
Real Time RT-PCR 
 
Primers pairs and TaqMan probes for P-gp/MDR1, MRP2, PXR, CAR, FXR, and 
HNF4α (TaqMan® Assay-on-Demand™ Products) as well as the constitutively 
expressed reference gene cyclophilin A (TaqMan® Pre-Developed Assay Reagents for 
Gene Expression) were obtained from Applied Biosystems (Foster City, CA).  All 
targeted ABC transporter and nuclear receptor probes were labeled with 6-
carboxyfluorescein (FAM)-dye while the cyclophilin A probe was labeled with VIC™-
dye.  All of the probes were quenched by 6-carboxytetramethylrohodamine (TAMRA) on 
the 3’ end.  Target gene probe sequences are summarized in Table 2-4.  In a 96-well 
reaction plate, 2.5 µL of 20X TaqMan Probe, 22.5 µL of human pediatric liver cDNA, 
and 25 µL of 2 X TaqMan Universal PCR Master Mix were added.  The reaction was 
performed in duplicate for each sample.  Real time reverse transcriptase-polymerase 
chain reaction (RT-PCR) was performed using the ABI Prism® Sequence Detection 
System 7000 (Applied Biosystems, Foster City, CA) using the default PCR thermal 
cycling conditions consisting of an initial TaqMan Universal PCR Master Mix activation 
at 50°C for 2 min, followed by an initial denaturation step at 95°C for 10 min, then 40 
cycles of 95°C for 15 sec and 60°C for 1 minute. 
 
Relative mRNA quantification was achieved through the standard curve or Ct (cycle 
threshold for target or endogenous control gene amplification) slope method.  The 
average Ct value was calculated from replicates of each sample using the ABI Sequence 
Detection System SDS software (Applied Biosystems, Foster City, CA).  MRP1, MRP2, 
PXR, CAR, FXR, HNF4A, and cyclophilin A standard curves were prepared from serial 
dilutions of cDNA from a HepG2 cell line.  Cyclophilin A (Cyc) was validated as the 
most stably transcribed reference gene across all age groups.  Dilutions included 1, 2, 4, 
8, and 20 fold initial cDNA concentration (C0).  A plot of Ct, the point at which the 
amplification plot cross the threshold cycle value, vs. C0 was then constructed (Figure 
2-1) as described by the assay manufacturer [78].  The threshold value was predetermined 
as 3 times the average baseline cycle value calculated from cycles 6 – 15.  The log 
concentration of the unknown samples was then calculated by linear regression from the 
standard curve.  The absolute concentration was then determined by taking its antilog 
value.  The expression level of each target gene was then calculated relative to the 
reference gene, cyclophilin A. 
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Table 2-4. Primer Sequence for Target Gene-Specific 5’-(FAM)-Labeled TaqMan® Assay-on-Demand™ Human Probes. 
 
Gene 
Symbol 
 
Alternative 
name 
 
Probe 5'-3' 
 
    
NCBI Gene 
Reference 
 
Target 
Exons 
 
     
ABCB1     
   
  
     
     
     
 
P-gp/MDR1
 
AGGTACCATACAGAAACTCTTTGAG
 
NM_000927 23
ABCC2
 
MRP2
 
ACCTCCAACAGGTGGCTTGCAATTC NM_000392 25
 NR1I2 PXR TACTTCAGGGACTTGCCCATCGAGG NM_033013.1 5
NR1I3 CAR GCCCCGGGATCGGTTTCTGTATGCG NM_005122.2 6
NR1H4 FXR ACAAAAAAGCTACCAGGATTTCAGA NM_005123.1 8
HNF4A
 
HNF4A
 
AAGGAAGCCGTCCAGAATGAGCGGG
 
NM_178849.1
 
3
 
Log Co
-1.4 -1.2 -1.0 -0.8 -0.6 -0.4 -0.2 0.0
C
t
22
24
26
28
30
32
34
MDR1 
MRP2 
PXR 
CAR 
FXR 
HNF4A 
 
 
Figure 2-1. Calibration Curve for MDR1, MRP2, PXR, CAR, FXR, and HNF4α. 
All targeted genes calibration curves have slopes of approximately -3.3, indicating an 
amplification efficiency of close to 1 within the linear range.  Ct, cycle threshold; C0, 
initial cDNA concentration
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Tissue Membrane Protein Isolation 
 
Liver tissue membrane protein for all human pediatric samples acquired from St. 
Jude Liver Bank was extracted by the ultracentrifugation method.  Briefly, approximately  
2 grams of frozen liver tissue, after quick thawing in a 37ºC water bath, was 
homogenized in 10 mL of homogenization buffer consisting of 0.1 M Tris pH 7.4, 0.1 M 
potassium chloride (KCL), 0.02 mM butylated hydroxytoluene (BHT), and 1 mM 
ethylenediamine tetraacetic acid (EDTA).  The tissue was further homogenized with a 
Teflon pestle at 800 rpm.  The homogenate was centrifuged at 12,000 g for 15 min at 
4°C.  The supernatant was discarded and the remaining pellet consisting of membrane 
proteins was resuspended in 5 mL of membrane storage buffer consisting of 20% 
glycerol, 1 mM DTT, 0.02 mM BHT, and 0.1 potassium phosphate (KPO4) pH 7.25.  
Aliquots of the membrane protein were prepared and stored in -70°C freezer until further 
processing. 
 
All membrane protein for samples received from the Medical College of Wisconsin 
were extracted by Calbiochem® ProteoExtract® Native Membrane Protein Extraction 
Kit (M-PEK).  Briefly, approximately 50 mg of liver tissue was homogenized in 2 mL of 
Extraction Buffer I and incubated for 10 minutes at 4°C under gentle agitation on a rotary 
shaker.  The homogenate was centrifuged for 15 minutes at 16,000 g and 4°C.  The 
supernatant was discarded and the pellet resuspended in 1 mL of Extraction Buffer II.  
The cell pellet was then incubated for 30 minutes at 4°C again under gentle agitation on a 
rotary shaker.  The cell suspension was centrifuged a second time at 16,000 x g and 4 °C 
for 15 minutes.  The resulting supernatant enriched in membrane proteins was then 
transferred to a fresh tube and stored in aliquots at -70°C until further processing. 
 
Protein quantification was determined through the Bradford assay [79] using bovine 
serum albumin (BSA; Sigma-Aldrich) as the standard.  Using a 96 well plate, stock BSA 
solution (0.2 mg/mL) was diluted to a final concentration ranging from 0 – 30 µg/mL 
with deionized water (dH20) in the standard wells.  In the sample wells, 1 µL of 
membrane protein from each pediatric liver sample was diluted in 199 µl of dH20.  50 µL 
of Protein Assay Dye Reagent Concentrate (Bio-Rad; complete information) was added 
to each well and mixed thoroughly.  All protein standards and unknown samples were 
repeated in triplicates.  The plate was incubated for 5 minutes at room temperature and 
the protein absorbance was read on a microplate reader at 595 nm.  A standard curve 
using the standard BSA absorbance (A) versus concentration was constructed.  All 
unknown protein concentrations were subsequently calculated by linear regression.  20 
µg of membrane protein from each liver sample was used for protein quantification. 
 
 
SDS-PAGE/Western Blotting 
 
To 20 µg of pediatric liver membrane protein, 2.5 mL of NuPAGE® LDS Sample 
Preparation Buffer (Invitrogen, Carlsbad, CA) was added.   The samples were 
fractionated via sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
using NuPAGE® 4 – 12 % Bis-Tris Polyacrylamide Gel with 1X NuPAGE® MOPS 
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Running buffer at 200 V for 1 hour.  On each gel, we also included a MultiMark® Multi-
Colored Protein Standard (Invitrogen, Carlsbad, CA) as well as positive controls for both 
MDR1/P-gp and MRP2.  Human P-gp membrane preparation (Human PGP membranes) 
and MRP2 membrane preparations (Human MRP2 membranes) were purchased from BD 
Gentest™ (Woburn, MA) and served as positive controls.  The separated proteins were 
transferred overnight onto an Invitrolon™ Polyvinylidene fluoride (PVDF) 0.2 µm 
membrane at 30 V using NuPAGE® 1X Transfer Buffer with 10% methanol. 
 
Nonspecific binding sites on the PVDF membrane were blocked using 5% nonfat 
dried milk in phosphate buffered saline (PBS) with 0.1% Tween (T) for one hour at room 
temperature.  The membrane was then incubated with the primary monoclonal antibody 
to P-gp (C219) (Alexis Biochemicals, San Diego, CA) diluted 1:100 fold, MRP2 (M2III-
6) (Alexis Biochemical, San Diego, CA) diluted 1:200 fold, or glyceraldehyde 3-
phosphate dehydrogenase (GAPDH, Sigma-Aldrich, St. Louis, MO) diluted 1:10000 fold 
in 5% nonfat dried milk in PBS with 0.1 % Tween (PBST) for 2 hours at room 
temperature.  After discarding the primary antibody, the membrane was washed 3 times 
with PBST each time for 5 minutes.  The membrane was then incubated for one hour 
with the secondary antibody, horseradish peroxidase-conjugated (HRP) Anti-Mouse IgG 
(Cell Signaling Technology, Danvers, MA), diluted in 5% nonfat dried milk in PBST 
either 1:5000 fold when probing P-gp and MRP2, or 1:10000 fold when probing for 
GAPDH.  GAPDH was chosen as the reference protein for the relative protein 
quantification since it was more stably expressed as compared to cyclophilin A.  After 3 – 
5 minute washings with PBST, the blots were then incubated with enhanced 
chemiluminescence ECL plus™ (GE Healthcare, Piscataway, NJ) for 5 minutes, and 
developed on Kodak® Biomax™ XAR autoradiography film (Sigma-Aldrich, St. Louis, 
MO) after 1 minute and 3 minute exposure times.  Protein band density was quantified 
using ImageJ [80] after digitizing the image using a flatbed scanner.   
 
 
Statistical Analysis 
 
All statistical analysis was performed using SPSS 14.0 (SPSS Inc., Chicago, IL).  
During real time PCR, an amplification plot, reported as ∆Rn vs. Ct, was generated for 
each sample (Figure 2-2).  ∆Rn represented the fluorescence emission intensity of the 
reporter minus the threshold Rn.  Threshold Rn was determined from the pre-set baseline.  
The Ct value for each sample was then used to back calculate an initial input amount by 
using the equation derived from the calibration curve regression line.  All data were back-
log transformed in order to achieve homoscedasticity, and target gene values were then 
normalized to the endogenous control cyclophilin A.  In order to achieve adequate power 
for statistical analysis, the liver samples were divided into four different age groups (A – 
D).  Group A included infants less than 8 months of age (<0.7years), group B represented 
infants from 8 months to 3 years of age (0.7 – <3 years), group C included those in the 
early childhood period from 3 years to 6 years of age (3 – <6 years), and group D 
included those in the late childhood period from 6 to 12 years of age (6 – 12 year).  
Samples where relative expression values were 1.5 times outside the 25th and 75th 
percentiles were considered outliers and removed prior to statistical analysis.  Less than  
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Figure 2-2. Representative Real Time PCR Amplification Plot for Target Human 
Genes. 
Ct, cycle threshold; ∆Rn, emission intensity of the reporter minus the threshold Rn.
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15% of the total sample size was considered outliers for each of the targeted gene 
expression.  Statistical comparison of mean values for target gene expression between 
each group was performed using one-way ANOVA with Bonferroni post-hoc test. 
 
Target gene mRNA expression = 
genereferenceofamountInitial
geneettofamountInitial arg  
 
Mean ± standard deviation (SD) values for all relative target gene mRNA 
expression were calculated for each age group.  Asterisks represent statistically 
significant differences (p < 0.05) in mean normalized mRNA expression between group 
A and the other age group(s).  Correlation between the nuclear receptors themselves and 
between the nuclear receptors and MDR1/P-gp and MRP2 was determined by linear 
regression analysis.  The goodness of fit is denoted by the r2 value and significance 
determined by the F test for simple linear regression. 
 
P-gp and MRP2 protein expression was detected by immunoblotting and quantified 
by band density.  The GAPDH bands were included in order to verify equal amount of 
protein loading for each sample.  Additionally, GAPDH was used as a reference gene in 
order to normalize the P-gp and MRP2 protein density.  Each blot was verified as within 
the linear range by comparing the 1 minute versus the 3 minute exposure.  Linearity 
curves constructed from known protein concentrations of control P-gp and MRP2 
membranes were also performed in order to verify linearity.  Non-detectable sample 
values were assigned a zero value and all data points were included in the analysis.
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Results 
 
 
mRNA Expression of MDR1/P-gp and MRP2 in Human Pediatric Liver Samples 
 
Using real time RT-PCR methodology, we were able to detect both ABC 
transporters MDR1 and MRP2 in all human pediatric liver samples.  Limited MDR1 and 
MRP2 mRNA expression was detected in the youngest age group – A (age range from 
0.25 - < 0.7 years old; approximately 4 – 8 months) but markedly increased with 
maturation (Figure 2-3).  Ontogenic mRNA expression of MDR1 and MRP2 was 
statistically significant between the youngest age group A and age group B.  
Interestingly, age group B MDR1 and MRP2 mRNA expression level surpassed not only 
age group A, but also age groups C and D.  For MDR1, age groups A, B, and C were 
36%, 157%, and 129% relative to age group D, respectively.  In a similar pattern, MRP2 
gene expression for age groups A, B, and C were 25%, 127%, 118% relative to age group 
D.  Though relative expression values in age groups C and D for MDR1 and MRP2 were 
higher than those in age group A, it was not statistically significant.  There appeared to be 
high variability in expression of the ABC transporters regardless of age group.  
Coefficient of variation for MDR1 ranged from 44 – 77% while those of MRP2 ranged 
from 13 – 72%.  Normalized mRNA expression values for individual human pediatric 
liver samples for MDR1 and MRP2 within each age group are represented in scatterplots.  
The values are also summarized in box and whiskers plots within each age group (Figure 
2-4 and Figure 2-5). 
 
 
mRNA Expression of Orphan Nuclear Receptors (NRs) in Human Pediatric Liver 
Samples 
 
Nuclear receptors PXR, CAR, FXR, and HNF4α mRNA expression overall showed 
very little age associated development as compared to the ontogenic expression exhibited 
by MDR1 and MRP2 (Figure 2-6 to Figure 2-9).  However, a general trend was observed 
for PXR, FXR, and HNF4α where expression levels were lowest in the youngest age 
group but increased to maximal levels by age groups B or C, and eventually decreased by 
age group D.  CAR expression appeared considerably different than the other nuclear 
receptors.  Expression level for CAR was actually highest in the youngest age group and 
gradually decreased with an increase in age.  Of all the nuclear receptors, FXR mRNA 
expression in the youngest age group A was the only group which exhibited significantly 
a lower expression value than the other age groups. 
 
In accordance with a recently published study [77], we were able to confirm the co-
expression between the mRNA expression of PXR, CAR, and HNF4α (Figure 2-10).  
Specifically, in human pediatric liver samples, HNF4α was positively correlated with 
PXR (r2 = 0.16, p = 0.002) and CAR (r2 = 0.14, p = 0.003).   While the literature supports 
evidence of HNF4α regulation of PXR and CAR, there have been no reports of HNF4α 
associated regulation of FXR.  We were able to provide evidence for the lack of 
correlation between HNF4α and FXR (r2 = 0.008, p = 0.49).
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Figure 2-3. Normalized Target Gene Expression. 
Relative target gene expression levels in human pediatric liver samples are represented as 
percentages (mean ± SEM) of those observed for the oldest age group D.  Asterisks 
represent significant differences (p < 0.05) in mean normalized target gene expression 
between age group A versus the other age group(s).  Y, years.
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Figure 2-4. mRNA Expression of MDR1/P-gp in Human Pediatric Liver Samples. 
Upper panel, box and whisker plot of cyclophilin A normalized MDR1 mRNA 
expression.  Boxes represent 25th and 75th percentiles and horizontal bars represent 10th 
and 90th percentiles while open circles represent outliers.  Mean ± SD for each age group 
are reported.  Lower panel, scatterplot of cyclophilin A normalized MDR1 mRNA 
expression versus age.  X-axis is on a discontinuous scale ranging from 0 – 8 months and 
> 8 months – 12 years.
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Figure 2-5. mRNA Expression of MRP2 in Human Pediatric Liver Samples. 
Upper panel, box and whisker plot of cyclophilin A normalized MRP2 mRNA 
expression.  Boxes represent 25th and 75th percentiles and horizontal bars represent 10th 
and 90th percentiles while open circles represent outliers.  Mean ± SD for each age group 
are reported.  Lower panel, Scatterplot of cyclophilin A normalized MRP2 mRNA 
expression versus age.  X-axis is on a discontinuous scale ranging from 0 – 8 months and 
> 8 months – 12 years.  
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igure 2-6. mRNA Expression of PXR in Human Pediatric Liver Samples. 
 
F
Upper panel, catterplot representation of cyclophilin A normalized PXR mRNA s
expression for individual liver samples vs. Age group.  Lower panel, box and whiskers 
plot of cyclophilin A normalized PXR mRNA expression in each age group.  Boxes 
represent 25th and 75th percentiles, horizontal bars represent 10th and 90th percentiles, 
and circles represent outliers.  Values indicate mean ± SD excluding outliers.
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Figure 2-7. mRNA Expression of CAR in Human Pediatric Liver Samples. 
Upper panel, scatterplot representation of cyclophilin A normalized CAR mRNA 
expression for individual liver samples vs. Age group.  Lower panel, box and whiskers 
plot of cyclophilin A normalized CAR mRNA expression in each age group.  Boxes 
represent 25th and 75th percentiles, horizontal bars represent 10th and 90th percentiles, 
and circles represent outliers.  Values indicate mean ± SD excluding outliers.
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Figure 2-8. mRNA Expression of FXR in Human Pediatric Liver Samples. 
Upper panel, scatterplot representation of cyclophilin A normalized FXR mRNA 
expression for individual liver samples vs. Age group.  Lower panel, box and whiskers 
plot of cyclophilin A normalized FXR mRNA expression in each age group.  Boxes 
represent 25th and 75th percentiles, horizontal bars represent 10th and 90th percentiles, 
and circles represent outliers.  Values indicate mean ± SD excluding outliers.  Asterisks 
indicate significant differences in mean target gene expression between age group A and 
the other age group(s) indicated. 
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Figure 2-9. mRNA Expression of HNF4α in Human Pediatric Liver Samples. 
Upper panel, scatterplot representation of cyclophilin A normalized HNF4α mRNA 
expression for individual liver samples vs. Age group.  Lower panel, box and whiskers 
plot of cyclophilin A normalized HNF4α mRNA expression in each age group.  Boxes 
represent 25th and 75th percentiles, horizontal bars represent 10th and 90th percentiles, 
and circles represent outliers.  Values indicate mean ± SD excluding outliers.
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Figure 2-10. HNF4α Correlations in Human Pediatric Liver Samples. 
Correlations between normalized target mRNA expression for nuclear receptors PXR, 
CAR, and FXR versus normalized HNF4α mRNA levels.  X-axis represents normalized 
HNF4α mRNA expression levels.  Y-axis is split into 3 different panels each representing 
normalized PXR, CAR, or FXR mRNA expression values.  Correlation between HNF4α 
and the corresponding nuclear receptor is indicated by the r2 value.  P-values are reported 
as well.  
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We also explored the correlations between the nuclear receptors and the drug 
ansporters (Figure 2-11 to Figure 2-13).  Expression of PXR was positively correlation 
with MDR1 (r2 = 0.20, p = 0.001) and to a lesser extent with MRP2 (r2 = 0.07, p = 0.04).  
In contrast, expression of CAR did not correlate with the expression of either drug 
transporters.  FXR expression in the human pediatric liver positively correlated with both 
MDR1 (r2 = 0.19, p = 0.001) and MRP2 (r2 = 0.13, p = 0.01) mRNA expression.   
 
 
Protein Expression of MDR1 and MRP2  
 
Western blot analysis of human pediatric liver samples revealed a single band at 
~170 kDa, ~190 kDa, and ~40 kDa corresponding to P-gp, MRP2, and GAPDH, 
respectively (Figure 2-14).  The successful detection of P-gp and MRP2 was verified by 
their positive controls.  Normalized protein expression was lowest in age group A as 
compared to the other age groups for both P-gp and MRP2 (Figure 2-15).  Age group B 
had the highest measured P-gp and MRP2 protein expression as compared to all other age 
groups.  After reaching the maximal expression level in age group B, both P-gp and 
MRP2 protein levels gradually decreased with increase in age.  Variability in protein 
expression for both transporters was high regardless of age group.  Coefficient of 
variation for P-gp ranged from 59 – 67% while those of MRP2 ranged from 46 – 90%.  
P-gp was non-detectable for 2% of the samples in age group A, but 100% was detected in 
all other age groups (Figure 2-15).  MRP2 was non-detectable in 50% of the samples in 
age group A, but detectable in 87%, 94% and 97% in age group B, C, and D (Figure 
2-16).  There were no significant differences in P-gp protein expression between the 
various age groups.  However for MRP2, protein expression was significantly higher in 
age groups B (p < 0.001), C (p < 0.01), and D (p < 0.05) than age group A. 
 
 
 
uclear receptors in animal models, there lacked sufficient evidence for the same 
association in human transporter development.  One of the main barriers in conducting 
such studies in humans has been simply the lack of availability of human pediatric 
samples.  Furthermore, archived samples in human tissue banks have often originated 
from donors diagnosed with disease (i.e. cancer), tissue pathologies, or exposure to drug 
therapy which may alter the expression of drug transporters or nuclear factors.  Also, a 
majority of samples stored in tissue banks originated from post-mortem donors.  
Unfortunately, RNA from post-mortem samples often has been unusable due to their 
rapid degradation by RNAses prior to cryopreservation.  In the present study, we were 
fortunate to obtain a large number of pediatric liver tissues preserved from living donors.  
As such, we were able to extract intact RNA as well as membrane proteins from these 
liver biopsies.  However, in order to gather more information regarding transporter  
tr
Discussion 
 
This study described the ontogeny of ABC transporters MDR1, MRP2, and of 
orphan nuclear receptors PXR, CAR, FXR, and HNF4α in human pediatric liver samples 
using real time RT-PCR and Western immunoblotting techniques.  While there have been
some published reports on the age associated expression of Mdr1/P-gp, Mrp2, as well as 
selected n
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Figure 2-11. PXR Correlations to MDR1 and MRP2. 
Correlation between normalized target m RNA 
expre s
RNA expression for MDR1 and MRP2 m
s ion versus normalized PXR mRNA levels. 
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Figure 2-12. CAR correlations to MDR1 and MRP2. 
Correlation between normalized target mRNA expression for MDR1 and MRP2 mRNA 
xpression versus normalized CAR mRNA levels. e
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Figure 2-13. FXR Correlations to MDR1 and MRP2. 
Correlation between normalized target mRNA expression for MDR1 and MRP2 mRNA 
expression versus normalized FXR mRNA levels. 
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Figure 2-14. Representative Western Immunoblots of MDR1/P-gp and MRP2 in 
Human Pediatric Liver Samples. 
Each column is a representative blot from each of the four age groups.  Human MDR1/ 
P-gp and MRP2 control membranes were included in each blot as a reference.  
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Figure 2-15. MDR1/P-gp Protein Expression in Human Pediatric Liver Samples.  
Upper panel, Box and whisker plot of normalized P-gp protein expression.  Boxes 
represent 25th and 75th percentiles and horizontal bars represent 10th and 90th 
percentiles while open circles represent outliers.  Mean ± SD for each age group are also 
shown as well as the percent of sample not detected within each age group (%ND).  
Lower panel, Scatterplot of normalized P-gp protein expression versus age.  X-axis is on 
a discontinuous scale ranging from 0 – 8 months and >8 months – 12 years.  
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igure 2-16. MRP2 Protein Expression in Human Pediatric Liver Samples. 
 within 
ll as 
 
discontinuous scale ranging from 0 – 8 months and >8 months – 12 years. 
F
Upper panel, Box and whisker plot of normalized MRP2 protein expression.  Boxes 
represent 25th and 75th percentiles and horizontal bars represent 10th and 90th 
percentiles while open circles represent outliers.  Bold print in text and asterisks
graph represent significant differences between the age group A versus the other 
indicated age groups (p < 0.05).  Mean ± SD for each age group are also shown as we
the percent of sample not detected within each age group (%ND).  Lower panel, 
Scatterplot of normalized MRP2 protein expression versus age.  X-axis is on a
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ontogeny in the early weeks after birth, we added postmortem liver samples to our 
original mRNA data set.  Due to RNA degradation in the postmortem samples, we were 
only able to measure protein and not mRNA content in those samples. 
 
For MDR1/P-gp gene expression, we were able to identify significantly lower 
mRNA expression between the early infant (before 8 months) and early childhood period 
(8 months – 3 years).  Our MDR1/P-gp protein expression in the pediatric liver samples, 
however, was not significantly different across the various age groups in our subset of 
protein samples.  The discordance in the relative expression of MDR1/P-gp mRNA and 
P-glycoprotein has been described in various cancer cell lines [81, 82].  This raises the 
possibility of post-transcriptional regulation of MDR1 as a potential source of variation 
for mRNA and protein expression in human pediatric liver samples.  van Kalken et al. 
reports a strong expression of P-gp in early human fetal liver development [65].  Our 
protein data extends their findings and supports high P-gp expression in the human 
pediatric liver from the neonatal throughout late childhood ages.  The crucial protective 
role P-gp plays in preventing intracellular endogenous or exogenous substrate 
accumulation would support its strong presence at birth especially in organs with 
excretory functions such as the liver and kidneys. 
 
Similar to MDR1/P-gp, MRP2 mRNA expression was significantly lower in the 
early infant months as compared to the early childhood period.  Furthermore, we were 
able to characterize the same relationship for MRP2 protein samples whereby the early 
infant period (birth – 8 months) exhibited the lowest MRP2 protein expression compared 
to all the other developmental periods.  The high occurrence of jaundice or 
hyperbilirubinemia often observed in premature infants and newborns may be partially 
attributed to the immature development of MRP2 at birth since MRP2 is the primary 
hepatic canalicular transporter that mediates various organic anions as well as sulfated or 
glucuronidated bile salts and bilirubin.  Our findings provide direct physiologic evidence 
of immature MRP2 expression in the early infant period of development.  Aside from 
bilirubin, immaturity of MRP2 expression at birth could also potentially impact the 
elimination of drug molecules that are substrates of MRP2.  Therefore, in the pediatric 
population, especially for newborns, medications with high biliary excretion may exhibit 
altered pharmacokinetic properties and thus, may necessitate special pediatric dosing or 
monitoring. 
 
The nuclear receptors PXR, CAR, and FXR are all involved in the co-regulation of 
drug metabolizing enzymes and drug transporters through activation of the response 
lements of their target genes.  Furthermore, there is a considerable level of overlap in the 
n PXR and 
 co-
les in 
 of FXR 
A1), 
cid 
e
inducers of both PXR and CAR.  This ‘cross-talk’ or ‘cross-regulation’ betwee
CAR provides redundancy in the regulation of their target gene expression such as the
expression of CYP3A4 and P-gp [56].  Though PXR, CAR, and FXR all have ro
human bile acid and lipid metabolism, FXR appears to be the main nuclear receptor 
charged with direct bile acid and cholesterol homeostasis.  Transcriptional targets
include ileal bile acid binding protein (IBABP), bile salt export pump (BSEP), sodium 
taurocholate contransporting peptide (NTCP), cholesterol 7-α hydroxylase (CYP7
and MRP2 – all metabolizing enzymes or transporters directly involved in bile a
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absorption, synthesis, or secretion [57, 71, 83].  In the present study, both the mean 
median mRNA expression values for PXR and FXR were lowest in the youngest age 
group and increased over time.  Our results support an ontogenically re
and 
gulated expression 
of PXR and FXR and appears to coincide with another study with limited human fetal 
liver 
.  
er 
determinant of PXR and CAR 
induction of CYP3A, may also play a significant role in the upregulation of P-gp given 
that C
k 
selves, we 
 as a constitutively expressed nuclear receptor whose activation of target 
gene receptors potentially occurs through a diffe
e 
samples which shows lower FXR mRNA expression as compared to adult liver 
samples [67].  However, unlike the PXR and FXR gene expression, CAR mRNA 
expression remained relatively constant throughout the different age groups.  CAR has 
been reported to be constitutively expressed and localized in the cytoplasm of 
hepatocytes.  Unlike PXR and FXR, CAR must translocate into the cell nucleus before 
activation of its target gene response elements [84].  Our results support a constitutive 
expression of CAR which does not appear to fluctuate with age. 
 
Apart from the developmental patterns in nuclear receptor expression, we also 
described a positive correlation between HNF4α, PXR, and CAR mRNA expression
The results agree with a previous study linking the co-expression between the nuclear 
receptors [77] and also support other findings that HNF4α is an important mast
regulator in coordinating the nuclear receptor mediated response to xenobiotics 
specifically in the liver [76].  HNF4α, as a critical 
YP3A and P-gp are often co-expressed and co-induced.  To date, there are no 
studies which suggest the regulation of FXR through HNF4α.  This is echoed by the lac
of correlation between HNF4α and FXR in the current study. 
 
Besides exploring the relationships between the nuclear receptors them
wished to also examine the correlations between the nuclear receptors PXR, CAR, and 
FXR and the drug transporters MDR1/P-gp and MRP2.  Significant correlations were 
detected between PXR and FXR along with MDR1/P-gp and MRP2.  In particular, the 
relationship between PXR and MDR1/P-gp was strongly correlated (p = 0.0001) while 
PXR and MRP2 was moderated associated (p = 0.04).  This corresponds with the role 
PXR plays in the coordinated regulation of drug metabolizing enzymes and drug 
transporters.  Conversely, CAR expression lacked correlation with either P-gp or MRP2.  
This was somewhat surprising given that CAR, similar to PXR, also serves as a crucial 
regulator of Phase I through Phase III drug disposition mechanisms.  Our findings 
support CAR
rent mechanism as compared to PXR.  In 
particular, the lack of direct correlation between CAR and drug transporter expression 
might be due to a multifaceted process whereby other co-regulators may be involved in 
CAR activation.  In contrast to CAR, both MDR1/P-gp and MRP2 were highly correlated 
with FXR expression.  Our findings support the role of FXR in maintaining bile acid 
homeostasis through its regulation of MDR1/P-gp as well as MRP2. 
 
The aims of the current study were to characterize the age associated development 
for ABC transporters MDR1/P-gp and MRP2 as well as nuclear receptors PXR, CAR, 
FXR, and HNF4α in human pediatric livers.  Our relatively large sample size included 
liver tissue from both living as well as deceased donors.  The liver samples from the 
living donors were analyzed for both mRNA and protein expression studies while th
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liver samples from the deceased donors were acquired in order to better characterize the 
ABC transporter protein expression especially in the newborn and infant periods.  Our
results revealed an age-associated expression whereby the youngest age group exhibited 
the lowest gene transcript level for MDR1/P-gp and MRP2 mRNA expression.  Protein
expression data, however, indicated only a significant age dependent expression of 
MRP2.  The dissociation in mRNA and protein expression in our MDR1/P-gp sam
might be the result of post-transcriptional regulation which would need to be 
substantiated with further research.   
 
For the nuclear receptors, we were able to establish a positive correlation between
HNF4α along with PXR and CAR, but not for FXR.  This appear
 
 
ples 
 
ed consistent with 
published literature which supports HNF4α as a master-regulator of PXR and CAR.  We 
also e  
RP2.  
t with 
in 
e possibility of additional 
co-regulators that may be involved in the activation of MDR1/P-gp and MRP2. 
 
 
netic 
xplored the relationships between the nuclear receptors and drug transporters in
order to ascribe the potential regulatory control of the nuclear receptors on the 
developmental patterns observed for MDR1/P-gp and MRP2.  We identified positive 
correlations between the nuclear receptors PXR and FXR with MDR1/P-gp and M
However, we were not able to detect correlations between CAR and the ABC 
transporters.  The correlations between PXR and ABC transporters seem consisten
the role of PXR as a major transcriptional regulator of drug metabolizing enzymes and 
drug transporters.  The role FXR serves as a main regulator of bile acid homeostasis 
the liver also supports its associations with MDR1/P-gp and MRP2.  The lack of 
correlations between CAR and the ABC transporters suggest th
 
The immaturity of human hepatic MRP2 in the early postnatal period described in
this study provides a partial explanation for the high incidence of hyperbilirubinemia in
newborns.  Besides endogenous substrates such as bilirubin and bile acids, the role of 
MRP2 as a major hepatic transporter of organic anions might also result in altered 
clearance of such pharmacological agents, particularly in newborns.  An important 
extension of the current study will be to examine the variability in the pharmacoki
parameters of medications with high biliary clearance in a system with impaired or 
deficient MRP2 expression. 
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CHAPTER 3.   AGE-ASSOCIATED EXPRESSION OF HEPATIC ABC DRUG 
TRANSPORTERS AND NUCLEAR RECEPTORS IN RAT LIVER  
 
 
Introduction 
 
Similar to humans, rodents also express the ABC drug transporters MDR1/P-gp and 
MRP2.  Unlike humans, however, rodent multidrug resistance protein MDR1/P-gp is 
encod
and 
ion 
o-
 
centr
f 
r 
ters Mdr1a/1b (P-gp) and Mrp2 has 
previously been explored in humans as detailed in Chapter 2.  Due to the limited 
availability of human pediatric liver biopsies, however, the use of animal tissues from 
various ages is often used as an alternative to gain knowledge about the ontogeny of drug 
disposition processes and has provided great insight into the developmental process of 
these drug transporters.  While there is a general consensus from the currently published 
animal studies on the fact that transporter expression is age-associated, some of the 
reported results are equivocal.  According to Rosati [63], gene expression of Mdr1a/1b 
increases around postnatal day 21 in the rat liver and reaches maximum expression by 
postnatal day 60.  However, western blots of mouse liver for P-gp indicates an abundance 
of P-gp at birth and throughout maturation into adulthood [62].  An age associated 
expression pattern has also been described for Mrp2 in the rat liver whereby Mrp2 gene 
expression increase significantly between postnatal days 6 – 12 and approaches a 
maximal expression value by day 30 [61, 63].  Similar to the studies by Rosati [63] and 
Gao [61], we have reported an ontogenic process in MRP2 mRNA and protein expression 
ed by two isoforms – Mdr1a (as referred to as Mdr3) and Mdr1b (Mdr1) [85-88].  
Mouse Mdr1a is highly expressed in the intestinal epithelium and at the blood–brain 
blood–testis barriers, whereas Mdr1b is highly expressed in the adrenal gland, pregnant 
uterus, and ovaries.  In addition, both genes are substantially expressed in many other 
tissues, including liver, kidney, lung, heart, and spleen [89, 90].  While tissue distribut
of Mdr1a/1b varies widely, these two highly homologous gene isoforms appear to be c
expressed in the mouse liver and contribute equally in the overall hepatic MDR1/P-gp 
function.  The sequence homology between rodent and human Mdr1-type genes is 
virtually complete [90-92].  Furthermore, rodent P-gp transport of various 
chemotherapeutic agents, endogenous glucocorticoids, as well as various exogenous drug
substrates are analogous to the function of human P-gp [88, 90, 93].   
 
Although it shares less than 20% amino acid identity with Mdr1/P-gp, Mrp2 
localization is very similar to Mdr1/P-gp including the intestines, liver, and kidney [41, 
94].  Similar to human MRP2 in both localization and function, rodent Mrp2 also plays a 
al role in the hepatobiliary excretion of various endogenous and exogenous 
substrates including bile acids, bilirubin, various organic anions, as wells as conjugates o
glucuronates, glutathiones, or sulfates [95, 96].  Mutations in the MRP2 gene can cause 
an autosomal recessive disorder which results in hereditary hyperbilirubinemia.  The 
human form of the mutation causes Dubin-Johnson syndrome, while in rats, a simila
mutation results in the EHBR (Esai hyperbillirubinemic rat) and the TR-strain of MRP2-
deficient rats [97]. 
 
Ontogenic regulation of ABC transpor
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in human pediatric liver samples of varying ages.  We also reported a significant age 
associated mRNA expression for MDR1/P-gp in the same pediatric liver samples. 
 
As mentioned in Chapter 2, orphan nuclear receptors include a gene superfamily of 
transc iptional factors that regulate the expression of its target genes, many of which 
include drug metabolizing enzymes an rters [70].  Paving the molecular 
regulatory pathway for their target gene expression, nuclear receptors may partly 
contr
 
 nuclear 
 our human 
pediatric liver samples, we were able to measure the mRNA expression of four different 
nucle R, 
r 
 
 
e ontogeny of rat liver Mdr1a/1b and Mrp2 by performing relative 
quantification for both mRNA and pr
uman 
l 
 
 
r
d drug transpo
ibute to the interindividual and ontogenic variability observed in drug transporter 
expression.  Nuclear receptors that target the expression of MDR1/P-gp and MRP2 
include PXR, CAR, and FXR [57, 58, 71, 72], while  HNF4α appears to be a master 
regulator of PXR and CAR [76].  Many of the ligands which activate transcription factors
within the nuclear receptors are drug substrates frequently used in pediatric 
pharmacotherapy including rifampin, phenobarbital, clotrimazole, and dexamethasone 
[98].  Even endogenous substrates such as bile acids and their precursors can modulate 
the downstream expression of drug transporters through activation or inhibition of 
nuclear receptors [72].   
 
Only two studies have so far investigated the ontogenic expression of
receptors [71, 77].  No study to date has examined the developmental patterns of nuclear 
receptors and their correlation to drug transporter development.  From
ar receptors involved in the regulation of MDR1/P-gp and MRP2 including PX
CAR, FXR, and HNF4α.  We were able to show a positive correlation between HNF4α, 
a master regulator of other nuclear receptor, and PXR and CAR expression.  Along the 
same lines, we were also able to identify positive correlations between the nuclea
receptors PXR and FXR to both ABC transporters. 
 
Knowledge regarding the developmental expression of ABC transporters as well
their regulation by nuclear receptors can provide crucial information regarding 
differences observed between pediatric and adult pharmacotherapy.  In the present study,
we characterized th
otein expression.  These data are generated to 
supplement our previous findings on the ontogeny of MDR1/P-gp and MRP2 in h
livers. The rat was chosen as model animal as it is the most established and well-
characterized model species for drug disposition, metabolism and toxicology.  To 
describe their developmental pattern of Mdr1a/1b and Mrp2 in more detail, we expanded 
upon the previous published studies by including more age groups ranging from postnata
day 0, 3, 7, 14, 21, 28, and adult rats (considered by sexual maturity by postnatal day 60) 
[99].  In addition, we also characterized the mRNA expression of regulatory 
transcriptional factors Pxr, Car, Fxr, and Hnf4α for the same rat liver samples.  We then
compared the mRNA expression between the four nuclear receptors in order to 
characterize their co-regulation.  Lastly, we investigated the correlations between the 
mRNA expression of the nuclear receptors and the drug transporters Mdr1a, Mdr1b, and
Mrp2. 
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Materials and Methods 
 
 
Samp
e 
rk 
d 
ed to 
the 
id nitrogen.  
 
cience 
lated to the sample acquisition were performed by Dr. Wenhui 
Zhang [100]. 
 
no 
 sodium acetate followed by 600 µL 
of phenol:chloroform:isoamyl alcohol was added to each homogenate, mixed thoroughly, 
and th 15 
queous 
ding the 
 10 – 
d pure with 
 
 
rst strand cDNA synthesis was performed by using the Superscript III kit 
nvitrogen, Carlsbad, CA) on an Eppendorf® Mastercycler™ (Westbury, NY).  Oligo dT 
was used as the primer for mRNA first-strand synthesis.  An aliquot totaling 1 µg of total 
le Acquisition 
 
Pregnant Sprague-Dawley (SD), 28 day-old, and adult aged (60 day-old) rats wer
acquired from Harland (Indianapolis, IN) and housed at 25ºC on a 12-hour light/da
cycle.  All animals were housed in standard laboratory cages and had free access to foo
and water throughout the entire study.  Pups delivered by the pregnant rats were rais
pre-determined ages including newborn, 3, 7, 14, and 21 days of age.  After reaching 
appropriate pre-determined age, six rats were selected at random and anesthetized with 
isoflurane .  Liver biopsies were dissected out and immediately frozen in liqu
All rats were sacrificed by creating a pneumothorax.  All frozen liver samples were 
stored at -70ºC until further processing.  The experimental protocol was approved by the
Animal Care and Use Committee (ACUC) of the University of Tennessee Health S
Center. All procedures re
 
 
Total RNA Isolation and cDNA Synthesis 
 
Total RNA from the rat livers was isolated using RNAgents® Total RNA Isolation
Kit (Promega, Madison, WI) according to manufacturer’s protocol.  Briefly, 
approximately 0.3 g of frozen liver was added to 600 µL of denaturing solution and 
homogenized using a handheld homogenizer for approximately 15 seconds or until 
fragments of tissue were visible.  Next, 60 µL of 2M
en vigorously shaken for 10 seconds.  After chilling the entire mixture on ice for 
minutes, the vials were centrifuged at 10,000 g for 20 minutes at 4ºC.  The top a
phase was transferred to a fresh centrifuge tube, and an equal amount of ice-cold 
isopropanol was then added in order to precipitate total RNA from the aqueous phase.  
Total RNA was precipitated for 30 minutes in a -20ºC freezer followed by a second 
centrifugation step at 10,000 g for 15 minutes.  The resulting RNA pellet was then 
washed with ice-cold 75% ethanol and re-pelleted by centrifugation.  After discar
ethanol, the RNA pellet was air dried and finally each RNA pellet was dissolved in
50 µL of nuclease-free water depending on the pellet size.  RNA concentrations were 
estimated by measuring its ultraviolet absorbance (A) at 260 nm and 280 nm, whereby 1 
absorbance unit (A260) = 40 µg of RNA/mL.  The purity of the RNA isolate was 
estimated by comparing the ratio for A260/A280.  RNA samples were considere
only minor protein contamination if the calculated ratio of A260/A280 was between 1.7 and
2.0.  Only samples with high purity were further processed for first strand cDNA
synthesis. 
 
Fi
(I
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RNA was mixed with 1 µL of 10  of 0.5 µg/µL Oligo(dT)12-18.  
he total mixture was then brought to 10 µL with the addition of DEPC-treated water.  
he mixture was incubated at 65ºC for 5 minutes on a heating block, then immediately 
st 1 minute.  A mixture of 2 µL of 10x RT buffer, 4 µL of 25 mM 
MgCl ™ recombinant RNase inhibitor, and 1 
µL of
y 
 
 
gene Cyclophilin A (TaqMan® Pre-Developed Assay Reagents for Gene 
Expression) were obtained from Applied Biosystems (Foster City, CA).  All targeted 
ABC transporter and nuclear receptor probes were labeled with 6-carboxyfluorescein 
abeled with VIC™-dye.  All of the probes 
were quenched by 6-carboxytetramethylrohodamine (TAMRA) on the 3’ end.  Target 
gene 
L of 2X 
le 
ence 
 
 
gure 
m the 
rve.  The absolute concentration was then determined by taking its antilog 
value.  The expression level of each target gene was then calculated relative to the 
refere
 mM dNTP mix and 1 µL
T
T
placed on ice for at lea
2, 2 µL of 0.1 M DTT, 1 µL of RNAseOUT
 SuperScript™ III reverse transcriptase was added to each reaction vial.  The entire 
mixture was then incubated for 50ºC for 50 minutes and the reaction was terminated b
increasing the temperature to 85ºC for 5 minutes.  Residual RNA was removed by adding
1 uL of RNAse H and incubating at 37ºC for 20 minutes.  The resulting cDNA was stored 
at -20ºC until real-time RT-PCR was performed.  
 
 
Real Time PCR 
 
  Primers pairs and TaqMan probes for Mdr1a, Mdr1b, Mrp2, Pxr, Car, Fxr, and 
Hnf4α (TaqMan® Assay-on-Demand™ Products) as well as the constitutively expressed
housekeeping 
(FAM)-dye while the cyclophilin probe was l
probe sequences are summarized in Table 3-1.   In a 96-well reaction plate, 2.5 µL 
of 20X TaqMan Probe, 22.5 µL of cDNA created from the rat liver, and 25 µ
TaqMan Universal PCR Master Mix were added.  The reaction was performed in 
duplicate for each sample.  Real time RT-PCR was performed using the ABI Prism® 
Sequence Detection System 7000 (Applied Biosystems, Foster City, CA) using the 
default PCR thermal cycling conditions consisting of an initial TaqMan Universal PCR 
Master Mix activation at 50°C for 2 min, followed by an initial denaturation step at 95°C 
for 10 min, then 40 cycles of 95°C for 15 sec and 60°C for 1 min.   
 
Relative mRNA quantification was achieved through the standard curve or Ct (cyc
threshold for target or endogenous control gene amplification) slope method.  The 
average Ct value was calculated from replicates of each sample using the ABI Sequ
Detection System SDS software (Applied Biosystems, Foster City, CA).  Mdr1a, Mdr1b, 
Mrp2, Pxr, Car, Fxr, Hnf4a, and cyclophilin A standard curves were prepared from serial
dilutions of cDNA from a standard adult rat sample.  Dilutions included 1, 2, 4, 10, and
20 fold initial cDNA concentration (C0).  A plot of Ct, the point at which the 
amplification plot cross the threshold cycle value, vs C0 was then constructed (Fi
3-1) as described by the assay manufacturer [78].  The threshold value was predetermined 
as 3 times the average baseline cycle value calculated from cycles 6 – 15.  The log 
concentration of the unknown samples was then calculated by linear regression fro
standard cu
nce gene, cyclophilin A. 
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Table 3-1. Primer Sequence for Target Gene-Specific 5’-(FAM)-Labeled TaqMan® Assay-on-Demand™ Rat Probes.  
 
       
Gene 
Symbol 
Alternative 
name Probe
   
   
 5
BI G
n'-3'     
NC
Refere
 
 
ene
ce 
 Target 
Exons 
 
 
Abcb1a Mdr1a TGAA
Abcb1 Mdr1b ACAT
Abcc2 Mrp2 TCAC
Nr1i2 Pxr CTAT
Nr1i3 Car TCAA
Nr1h4 Fxr GGG
Hnf4α Hnf4α CATG
   
AGGGGCTACAGGGTCTAGGCT NM_1
GGCCATGTACGCCTACTATTA NM_0
ATCCAGGGATCCACAGCCTA NM_0
CTGCACACAGGTTCCTGTTC NM_0
GACTCCAAAGTCGGTTTCTGT NM_0
TGCAAAGGTTTCTTCCGAAGA NM_0
AAGAAAGAAGCCGTCCAAAAT NM_0
 
3 .1
12623.2
C 12833.1
C 52980.1
22941.2
C 21745.1
22180.1
3401 20 
5 
14 
8 
7 
3 
3 
 
 52
 Log Co
-2.5 .0 -0.5 0.0
C
t
-2.0 -1.5 -1
15
35
40
20
25
30
mdr1a 
mdr1b 
mrp2 
pxr 
car 
fxr 
hnf4a 
 
Figure 3-1. α. 
Serial dilutions of cDNA created from a reference sample taken from an adult rat.  All 
targeted genes calibration curves have slopes of approximately -3.3, indicating an 
amplification e e linear range.
Calibration Curve for Mdr1a, Mdr1b, Mrp2, Pxr, Car, Fxr, and Hnf4
fficiency of close to 1 within th
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Tissue Membrane Protein Isolation 
 
Membrane proteins for all rat liver samples were extracted through the 
Calbiochem® ProteoExtract® Native Membrane Protein Extraction Kit (M-PEK) 
according to the manufacturer protocol.  Briefly, approximately 50 mg of liver tissue was 
homogenized in 2 mLs of Extraction Buffer I and incubated for 10 minutes at 4°C under 
gentle agitation on a rotary shaker.  The homogenate was centrifuged for 15 minutes at 
16,000 g and 4°C.  The supernatant was discarded and the pellet resuspended in 1 mL of 
Extraction Buffer II.  The cell pellet containing membrane and cytosolic proteins was 
then incubated for 30 minutes at 4°C again under gentle agitation on a rotary shaker.  The 
cell suspension was centrifuged a second time at 16,000 x g and 4 °C for 15 minutes.  
The resulting supernatant enriched in membrane proteins was then transferred to a fresh 
tube and stored in aliquots at -70°C until further processing. 
 
Protein quantification was determined by the method of Bradford Assay [79] using 
bovine serum albumin (BSA; Sigma-Aldrich) as the standard.  Using a 96 well plate, 
stock BSA solution (0.2 mg/mL) was diluted to a final concentration ranging from 0 – 30 
µg/mL with dH20 in the standard wells.  In the sample wells, 1 µL of membrane protein 
from each pediatric liver sample was dilute in 199 µl of dH20.  50 µL of Protein Assay 
Dye Reagent Concentrate (Bio-Rad) was added to each well and mixed thoroughly.  All 
 (A) 
oncentrations were 
subsequently calculated using the standard curve.  20 µg of membrane protein from each 
liver sample was used for protein quantification. 
 
 
SDS-PAGE/Western Blotting 
 
To 20 µg of rat liver membrane protein, 2.5 mL of NuPAGE® LDS Sample 
Preparation Buffer (Invitrogen, Carlsbad, CA) was added.   The samples were 
fractionated via SDS-PAGE using NuPAGE® 4 – 12 % Bis-Tris Gel with 1X NuPAGE® 
MOPS Running buffer at 200 V for 1 hour.  On each gel, we also included a MultiMark® 
Multi-Colored Protein Standard molecular weight ladder (Invitrogen, Carlsbad, CA).  
Human P-gp membrane preparation (Human PGP membranes) and MRP2 membrane 
preparations (Human MRP2 membranes) purchased from BD Gentest™ (Woburn, MA) 
were also included on each gel as positive controls.  The separated proteins were 
transferred overnight onto a Invitrolon™ PVDF 0.2 um membrane at 30 V using 
NuPAGE® 1X Transfer Buffer with 10% methanol. 
 
Nonspecific binding sites on the PVDF membrane were blocked using 5% nonfat 
dried milk in phosphate buffered saline (PBS; pH 7.4) with 0.1% Tween for 1 hour at 
room temperature.  The membrane was then incubated with a primary monoclonal 
antibody to P-gp (C219) (Alexis Biochemicals, San Diego, CA) diluted 1:100 fold, 
MRP2 (M2III-6) (Alexis Biochemical, San Diego, CA) diluted 1:200 fold, or GAPDH 
protein standards and unknown samples were measured in triplicates.  The plate was 
incubated for 5 minutes at room temperature and the protein absorbance was read on a 
microplate reader at 595 nm.  A standard curve using the standard BSA absorbance
versus concentration was constructed.  All unknown protein c
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(Sigma-Aldrich, St. Louis, MO) diluted 1:10000 fold in 5% nonfat dried milk in PBS 
with 0.1 % Tween (PBST) for 2 hours at room temperature.  After discarding the primary 
antib tes.  The 
gated 
 
 
Stati
 
y 
k-
ivided 
ch group was performed using one-way 
ANOVA with Bonferroni post-hoc test. 
 
ion =
ody, the membrane was washed 3 times with PBST each time for 5 minu
membrane was then incubated for 1 hour with the secondary antibody, HRP-conju
Anti-Mouse IgG (Cell Signaling Technology, Danvers, MA), diluted in 5% nonfat dried 
milk in PBST either 1:5000 fold when probing P-gp and MRP2, or 1:10000 fold when 
probing for GAPDH.  After 3 – 5 minute washings with PBST, the blots were then 
incubated with enhanced chemiluminescence ECL plus™ (GE Healthcare, Piscataway, 
NJ) for 5 minutes, then developed on Kodak® Biomax™ XAR autoradiography film 
(Sigma-Aldrich, St. Louis, MO) after 1 minute and 3 minute exposure times.  Protein 
band density was quantified using ImageJ [80] after digitizing the image using a flatbed
scanner. 
 
stical Analysis  
 
All statistical analysis was performed using SPSS 14.0 (SPSS Inc., Chicago, IL).  
During real time PCR, an amplification plot, reported as ∆Rn vs. Ct, was generated for 
each sample (Figure 3-2).  ∆Rn represented the fluorescence emission intensity of the 
reporter minus the threshold Rn.  Threshold Rn was determined from the pre-set baseline. 
The Ct value for each sample was then used to back calculate an initial input amount b
using the equation derived from the calibration curve regression line.  All data were bac
log transformed in order to achieve homoscedasticity, and target gene values were then 
normalized to the endogenous control cyclophilin A.  The rat liver samples were d
into seven age groups (0, 3, 7, 14, 21, 28 day-old, and adult).  Statistical comparison of 
mean value for target gene expression between ea
Target gene mRNA express  
genereferenceofamountInitial
 
Mean ± standard deviation (SD) values for all relative target gene mRNA 
expression were calculated for each rat age group.  Statistically significant results (p < 
0.05) are denoted with asterisks.  Correlation between the nuclear receptors themselves 
and between the nuclear receptors and the ABC transporters was determined.  The 
goodness of fit is denoted by the r
geneettofamountInitial arg  
tified 
 order to verify equal amount of 
prote
ere 
2 value and significance determined by the F test for 
simple linear regression. 
 
P-gp and Mrp2 protein expression was detected by immunoblotting and quan
by band density.  The Gapdh bands were included in
in loading for each sample.  Additionally, Gapdh was used as a reference gene in 
order to normalize the P-gp and Mrp2 protein density.  Each blot was verified as within 
the linear range by comparing the 1 minute versus the 3 minute exposure.  Samples wh
relative expression values were 1.5 times outside the 25th and 75th percentiles were 
 55
 Ct
15 20 25 30 35 40
R
n
-2
0
2
4
6
8
10
12
14
16
18
Mdr1a
Mdr1b 
Mrp2 
Pxr 
Car 
Fxr 
Hnf4α 
 
Figure 3-2. Sample Real Time PCR Amplification Plot for Target Rat Genes. 
∆Rn represents the fluorescence emission intensity of the reporter minus the threshold R.
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considered outliers and removed prior to analysis.  Again, statistical analysis was 
performed using one-way ANOVA followed by Bonferroni post-hoc test.  Statistically 
significant results (p < 0.05) are denoted with asterisks. 
 
 
Results  
 
 
mRNA Expression of Mdr1a, Mdr1b, and Mrp2 in Rat Liver Samples 
 
Using real time RT-PCR methodology, we were able to detect ABC transporters 
Mdr1a, Mdr1b and Mrp2 in all rat liver samples.  Compared to the adult rat group, the 
relative Mdr1a expression in 0, 3, 7, 14, 21, and 28 day-old age groups were 10.6%, 
7.0%, 23.6%, 26.1%, 96.5%, and 157.5%, respectively (Figure 3-3).  Limited Mdr1a 
mRNA expression was detected for 0 and 3 days old rats followed by a gradual increase 
in the 7 and 14 days old age groups (Figure 3-4).  Mdr1a mRNA expression dramatically 
increased between 14 and 21 days, and eventually reached maximal expression level by 
28 days.  Significant differences in mean Mdr1a mRNA expression values were detected 
for 0, 3 and 7 day-old rat groups as compared to the 28 day-old group.    
 
3, 7, 
days of age (Figure 3-5).  Mdr1b mRNA expression then increased between 14 and 21 
days and reached a peak in 28 days of age.  Mdr1b expression values were 39.2%, 11.3%, 
49.6%, 52.1%, 76.2%, and 169.5% of the adult group for groups 0, 3, 7, 14, 21, and 28 
days-old (Figure 3-3).  Though mean values suggested an age-associated gene expression 
for Mdr1b, statistical analysis revealed no significant differences between any of the age 
groups. 
 
Similar to Mdr1a and Mdr1b, rat liver Mrp2 expression remained low in the 
younger age groups from 0 days throughout 21 days.  However, Mrp2 expression 
dramatically increased between 21 day- and 28 day-old rats and eventually reached 
maximal values by adult age (Figure 3-6).  When compared to adult aged rats, expression 
values were 10.7%, 11.9%, 22.1%, 12.4%, 26.1%, and 75.4% in the 0, 3, 7, 14, 21, and 
28 day-old rats, respectively (Figure 3-3).  Statistical analysis revealed significant 
differences between age groups 0, 3, 7, 14, and 21 days-old versus the adult rats.  There 
was no difference detected for Mrp2 mRNA expression between 28 day-old and adult 
rats. 
 
 
mRNA Expression of Orphan Nuclear Receptors (NRs) in Rat Liver Samples 
 
Similar to the rat hepatic ABC transporters, the nuclear receptors Pxr, Car, and 
Fxr all exhibited age-associated expression.  Pxr gene expression for newborn rats was 
approximately 49% of adult Pxr expression but decreased gradually to between 25% - 
35% between 3 through 21 days of age before increasing back to approximately 56% of  
Low expression values were measured for Mdr1b in the early age groups 0, 
throughout 14 days-old rats which then increased to a maximal expression value by 28 
 57
 0
250
3 00
0 Days 
3 Days 
7 Days 
14 Days 
21 Days 
on
/
 A
Mdr1a Mdr1b Mrp2
Ta
rg
et
 m
R
N
A
 e
xp
re
ss
i
C
yc
lo
ph
ilin
28 Days 
Adult 200
50
100
150
* * * * * * ** *
 
 
Figure 3-3. Ontogeny of Mdr1a, Mdr1b, and Mrp2 Expression in Rat Liver Samples. 
Values are normalized target gene expression relative to the adult liver group.  Asterisks 
(*) represents significant differences (p < 0.05) between the various age groups as 
compared to the adult group.
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Figure 3-4. Ontogeny of Normalized Mdr1a mRNA Expression in Rat Liver Samples. 
Upper panel. scatterplot of normalized Mdr1a mRNA expression of individual rats by 
each age group. Lower panel, bar graph presenting mean ± standard deviation from six 
rat liver samples in each age group.  Mdr1a, mdr1-type isoform a of the rat multidrug 
resistance gene P-glycoprotein. 
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Figure 3-5. Ontogeny of Normalized Mdr1b mRNA Expression in Rat Liver Samples. 
Upper panel. scatterplot of normalized Mdr1b mRNA expression of individual rats by 
each age group. Lower panel, bar graph presenting mean ± standard deviation from six 
rat liver samples in each age group. Mdr1b, mdr1-type isoform b of the rat multidrug 
resistance gene P-glycoprotein.
 60
0 Days 3 Days 7 Days 14 Days 21 Days 28 Days Adult
M
rp
2 
m
R
N
A/
C
yc
lo
ph
ili
n 
A
 m
R
N
A
0.0
0.5
1.0
1.5
2.0
2.5
3.0
  
0 Days 3 Days 7 Days 14 Days 21 Days 28 Days Adult
M
rp
2 
m
R
N
A
/C
yc
lo
ph
ilin
 A
 m
R
N
A
0.0
0.5
1.0
1.5
2.0
2.5
* * * * *
 
. Figure 3-6. Ontogeny of Normalized Mrp2 mRNA Expression in Rat Liver Samples
Upper panel. scatterplot of normalized Mrp2 mRNA expression of individual rats by 
each age group. Lower panel, bar graph presenting mean ± standard deviation from six 
rat liver samples in each age group.  Mrp2, rat multidrug resistance-associated protein 2.
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adult values by 28 days of age.  Car gene expression followed a similar developmental 
pattern as Pxr.  Newborn rat liver Car mRNA expression was approximately 20 – 25% of 
adult expression in the first 3 weeks of life, but dramatically increased to approximately 
59% by 28 days of age.  Fxr mRNA expression was initially 30% of adult at birth through 
3 days of age.  Expression then spiked to 40% in 7 days of age before decreasing to 26% 
in 14 day-old rats.  By 21 days, Fxr gene expression had climbed to 45%, and by 28 days 
it had reached 65% of adult Fxr expression.  Age associated mRNA expression for Hnf4α 
in the same rat livers, however, was slightly different then the other nuclear factors.  
Newborn rat liver Hnf4α was only 50% of adult values at birth, but decreased to 26% by 
3 days of age, and eventually increased back to 56% by 7 days of age before dropping 
back to 25% by 14 days of age.  Hnf4α in rat livers then increased from 69% to 93% of 
adult expression by 21 and 28 days of age, respectively (Figure 3-7). 
 
Statistical comparisons revealed significance in Pxr expression between all age 
groups ranging from newborn through 28 days-old rats as compared to adult rats (Figure 
3-8).  The same was true for Car where significant differences were detected in mRNA 
expression between newborn through 21 day-old rat livers versus adult rat livers (Figure 
3-9).  Fxr mRNA expression in newborns through 21 day-old rat livers were significantly 
different than adult liver expression as well (Figure 3-10).  Unlike all the other nuclear 
receptors, Hnf4α did not exhibit any significant age associated expression between any of 
the age groups examined (Figure 3-11). 
 
In order to investigate the coordinated regulation between nuclear receptors, we 
also compared the normalized mRNA expression of Pxr, Car, and Fxr versus Hnf4α.  We 
were able to detect a positive correlation between all three nuclear receptors and Hnf4α 
in the rat liver samples.  Pxr was positively correlated with Hnf4α (r2 = 0.22, p = 0.003) 
and Car (r2 = 0.28, p < 0.001). Fxr also exhibited a positive correlation to Hnf4α with (r2 
= 0.59, p < 0.001).  Next, we compared the correlations between the rat hepatic nuclear 
receptors and the ABC transporters (Figure 3-12 to Figure 3-15).  mRNA expression of 
all three nuclear receptors (Pxr, Car, and Fxr) were positively correlated with those of the 
ABC transporters (Mdr1a, Mdr1b, and Mrp2).  Expression of Pxr was positively 
correlated with Mdr1a (r2 = 0.28, p < 0.001), Mdr1b (r2 = 0.32, p < 0.001), and Mrp2 (r2 
= 0.29, p < 0.001).  Similar, but weaker correlations were observed for Car and Mdr1a (r2 
= 0.22, p < 0.01), Mdr1b (r2 = 0.23, p < 0.01), and Mrp2 (r2 = 0.26, p < 0.01).  Much 
stronger correlations were detected between Fxr and Mdr1a (r2 = 0.44, p < 0.01), Mdr1b 
(r2 = 0.34, p < 0.01), and Mrp2 (r2 = 0.83, p < 0.01).   
 
 
 
 
groups.  The lowest Mdr1/P-gp protein expression occurred in the 0, 3, and 7 day-old rat 
livers at 25% and 46% of adult protein levels, respectively (Figure 3-16).  Statistically, 0,  
Protein Expression of Mdr1/P-gp and Mrp2 in Rat Liver Samples
 
We were successful in quantifying Mdr1/P-gp and Mrp2 protein expression for rat
liver samples ranging from newborns throughout adults.  For Mdr1/P-gp, relative protein
expression was highest in the 28 days-old group followed by the 14 and 21 day-old 
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Figure 3-7. Ontogeny of Nuclear Receptors Pxr, Car, Fxr, and Hnf4α in Rat Liver 
Samples. 
Values are normalized target gene expression relative to the adult liver group.  Asterisk 
(*) represents a significant difference as compared to the adult group (p < 0.05).  Pxr, 
pregnane X receptor; Car, constitutive androstane receptor; Fxr, farnesoid X receptor; 
Hnf4α, hepatic nuclear factor 4α.
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Figure 3-8. Ontogeny of Normalized Pxr mRNA Expression in Rat Liver Samples. 
Upper panel. scatterplot of normalized Pxr mRNA expression of individual rats by each 
age group. Lower panel, bar graph presenting mean ± standard deviation from six rat 
liver samples in each age group.  Pxr, pregnane X receptor. 
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Figure 3-9. Ontogeny of Normalized Car mRNA Expression in Rat Liver Samples. 
Upper panel. scatterplot of normalized Car mRNA expression of individual rats by ea
age group. Lower panel, bar graph presenting mean ± standa
li
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Figure 3-10. Ontogeny of Normalized Fxr mRNA Expression in Rat Liver Samp s. 
 s  
le
Upper panel. catterplot of normalized Fxr mRNA expression of individual rats by each
age group. Lower panel, bar graph presenting mean ± standard deviation from six rat 
liver samples in each age group.  Fxr, farnesoid X receptor. 
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Figure 3-11. Ontogeny of Normalized Hnf4α mRNA Expression in Rat Liver Samples.
Upper panel. scatterplot of normalized Hnf4α mRNA expression of individual rats by 
each age group. Lower panel, bar graph presenting mean ± standard deviation from six 
rat liver samples in each age group.  Hnf4α, hepatic nuclear factor 4
 
α. 
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Figure 3-12. Hnf4α Correlation Analysis in Rat Liver Samples. 
Correlation between normalized target mRNA expression for nuclear receptors Pxr, Car, 
and Fxr versus normalized Hnf4α (Hnf4a) mRNA levels.  X-axis represents normalized 
Hnf4α mRNA expression levels.  Y-axis is split into 3 different panels each representing 
normalized Pxr, Car, or Fxr mRNA expression values.  Correlation between Hnf4α and 
the corresponding nuclear receptor is indicated by the r2 value.  A p-value for each 
correlation is reported as well.
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Figure 3-13. Pxr Correlations to Mdr1a, Mdr1b, and Mrp2. 
Correlation between normalized target mRNA expression for Pxr versus normalized 
target ABC transporter levels.  X-axis represents normalized Pxr mRNA expression 
levels.  Y-axis is split into 3 different panels each representing normalized Mdr1a, 
Mdr1b, or Mrp2  mRNA expression values.  Correlation between Pxr and the 
corresponding ABC transporte 2r is indicated by the r  value.  A p-value for each 
correlation is reported as well.
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Figure 3-14. Car Correlations to Mdr1a, Mdr1b, and Mrp2. 
alized target mRNA expression for Pxr versus normalized 
RNA expression 
Correlation between norm
target ABC transporter levels.  X-axis represents normalized Car  m
levels.  Y-axis is split into 3 different panels each representing normalized Mdr1a, 
Mdr1b, or Mrp2  mRNA expression values.  Correlation between Car and the 
corresponding ABC transporter is indicated by the r2 value.  A p-value for each 
correlation is reported as well. 
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Figure 3-15. Fxr Correlations to Mdr1a, Mdr1b, and Mrp2. 
Correlation between normalized target mRNA expression for Pxr versus normalized 
target ABC transporter levels.  X-axis represents normalized Fxr  mRNA expressio
levels.  Y-axis is split into 3 different panels each representing normalized Md
Mdr1b, or Mrp2  mRNA expression values.  Correlation between Fxr and the 
corresponding ABC transporter 2
n 
r1a, 
 is indicated by the r  value.  A p-value for each 
orrelation is reported as well. 
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Figure 3-16. Ontogeny of Mdr1a and Mrp2 Protein Expression in Rat Liver Samples. 
Values are normalized target gene expression relative to the highest expression group.  
Asterisks (*) represent significant differences (p < 0.05) between the various age groups 
as compared to the adult group.
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3, and 7 day-old rat liver samples all had significantly lower Mdr1/P-gp expression (p < 
0.05) than the 28 day-old rat livers (Figure 3-17). 
 
Mrp2 relative protein expression in the rat liver remained low in the first weeks of 
life and eventually reached maximal value by adulthood.  0 and 3 day-old livers 
expressed 14% and 15% of adult liver Mrp2, while 7 day-old rat livers expressed almost 
10% of adult Mrp2 content.  Mrp2 protein expression increased gradually to 
approximately 60% of adult expression between 14 and 28 days of age (Figure 3-16).  
Significant differences (p < 0.05) were detected between the 0, 3, and 7 day-old versus 
adult liver groups (Figure 3-18). 
 
Protein expression for both Mdr1 and Mrp2 overall matched those from the relative 
mRNA expression in the same liver samples.  In general, Mdr1/P-gp protein and mRNA 
expression were low in the 0, 3, and 7 day-old groups and increased to a maximal level 
later in during postnatal development.  Likewise, Mrp2 values for both mRNA and 
protein expression remained low early in life and gradually increased to maximal values 
throughout postnatal maturation.  For Mdr1/P-gp protein expression, 14 day-old rat liver 
samples did not exhibit a significant difference as compared to 28 day samples as was for 
the Mdr1a mRNA expression data.  Similarly for Mrp2, 14 and 21 day-old liver protein 
expression was not significantly different from the adult samples as suggested by the 
Mrp2 mRNA expression data.   
 
amined the ontogeny of ABC transporters Mdr1a, 
Mdr1b, and Mrp2 as well as nuclear receptors Pxr, Fxr, Car, and Hnf4α in rats during 
seven specific time points throughout maturation ranging from newborn to adult.  For the 
transporters, we performed both real-time RT-PCR as well as Western immunoblots in 
order to semi-quantitate their mRNA and protein expression.  For the nuclear receptors, 
we characterized their mRNA expression using real-time RT-PCR.  We were able to 
describe an ontogenic process in rat liver Mdr1/P-gp as well as Mrp2 mRNA and protein 
expression.  An age-associated expression was also described for the nuclear receptors 
Pxr, Car, and Fxr. 
 
Overall, mRNA expression for Mdr1a, Mdr1b, and Mrp2 were low throughout the 
first three weeks of life.  For Mdr1a and Mdr1b, normalized mRNA expression increased 
from 21 day-olds liver samples to a maximal expression level by 28 days of age before 
declining to adult levels.  The Mdr1a results were similar to those reported by Rosati [63] 
where mRNA levels were less than 50% of 60 days-old rats from birth until 
approximately 12 days-old in the rat liver.  While the Mdr1b mRNA expression pattern 
was similar to that obtained by Rosati [63], we could not detect significant differences 
between the age groups.  Mrp2 expression in the rat liver increased gradually from 0 
days-old through 21 days of age before reaching 75% of adult expression values by 28 
 
Discussion 
 
In the current study, we ex
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Figure 3-17. Ontogeny of Normalized Mdr1/P-gp Protein Expression in Rat Liver 
Samples. 
Upper panel. scatterplot of normalized Mdr1/P-gp protein expression of individual rats 
by each age group.  Lower panel, bar graph presenting mean ± standard deviation from 
six rat liver samples in each age group. Asterisks (*) represents a significant differenc
< 0.05) compared to the 28 day-old group.  Underneath the mean ± standard deviation b
e (p 
ar 
graph is a representative western immunoblot of two Mdr1/P-gp samples from each 
corresponding age group.  Mdr1, multidrug resistance 1 gene/P-glycoprotein.
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Figure 3-18. Ontogeny of Normalized Mrp2 Protein Expression in Rat Liver Samples. 
Upper panel. scatterplot of normalized Mrp2 protein expression of individual rats by 
each age group.  Lower panel, bar graph presenting mean ± standard deviation from six 
rat liver samples in each age group. Asterisks (*) represents a significant difference (p < 
0.05) compared to the adult group.  Underneath the mean ± standard deviation bar graph 
is a representative western immunoblot of two Mrp2 samples from each corresponding 
age group Mrp2, multidrug resistance-associated protein 2.
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days of age.  This pattern was consistent with the results of Rosati [63], where adult rat 
liver Mrp2 expression was significantly greater than that of rats less than one week old.  
Similar findings were reported by Gao [61], where Mrp2 mRNA expression in rat livers 
from birth throughout 20 days of age fluctuated between 25 – 84% of adult values.  
Zinchuk [101] also reported less than 50% of adult Mrp2 mRNA expression in those rat 
livers less than one week of age.  
 
Protein expression for Mdr1/P-gp in general matched those detected for mRNA 
expression in our study.  Mdr1/P-gp protein levels remained low throughout postnatal 
maturation but increased dramatically between 14 days of age and adulthood.  This 
observation, however, was in contrast to a report by Mahmood [62], who stated that 
Mdr1/P-gp protein levels were greater than 100% in the newborn, 7 day-, and 21 day-old 
mouse liver as compared to adult mouse liver.  
 
Similar to the Mdr1/P-gp results, Mrp2 protein expression in the rat livers also 
mimicked their mRNA expression pattern.  Both Mrp2 mRNA and protein expression 
were less than 60% of adult values during the first 14 postnatal days, but increased to a 
maximal level by adulthood.  The only divergence between protein and mRNA
expression was that 14 day-old rat livers exhibited higher protein content then the mRNA 
levels.  Again, the developmental pattern was in agreement with those reported for rat 
Mrp2 protein by Rosati [63], Gao [61], and Zinchuk [101].  Rosati [63] detected Mrp2 
proteins in 15 day-old rats through immunoblotting while Gao [61], through 
immunostaining of rat livers, was able to demonstrate positive canalicular 
immunofluorescence comparable to those of adult rat livers in postnatal day 12 rats. 
 
Regulators of Mdr1/P-gp and Mrp2 include nuclear receptors Pxr, Car, and Fxr [57, 
58, 71, 72], while Hnf4α functions as a master regulator of Pxr and Car [76].  Given our 
observation of the age dependency in Mdr1/P-gp and Mrp2 expression during rat liver 
maturation, we also investigated the ontogenic expression of nuclear receptors as a 
potential regulatory mechanism for the transporter expression.  We were able to detect 
significant differences in nuclear receptor expression for Pxr, Car, and Fxr throughout the 
early postnatal period versus adulthood.  Specifically, we described a developmental 
pattern for Pxr and Car whereby rat livers from 0 to 21 postnatal days initially exhibited a 
high transcript level at birth but gradually declined to 25% and 19% of adult levels by 21 
days of age.  However, by 28 days of age, both rat liver Pxr and Car expression
dramatically increased to those near adult levels.  Unlike Pxr and Car, Fxr expression in 
the rat livers followed a more gradual increase throughout maturation.  Fxr mRNA 
xpression started  approximately 30% of adult levels at birth and gradually rose to 
 
] 
 
 
 
e  from
65% of adult levels by postnatal week 4.  Our results were similar to previously published
results from Balasubramaniyan [71] and Huang [102] and further support the regulatory 
role of nuclear receptors in age associated transporter expression.  Balasubramaniyan [71
provided evidence of limited Pxr and Fxr expression in rats less than four week of age as 
compared to adult rats while Huang [102] reported that in mouse livers, expression of Car
mRNA was significantly lower in the first week of life as compared to adult mice.  
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Nuclear receptors are considered crucial regulatory elements for the coordinated 
expression of drug metabolizing enzymes and drug transporters, specifically those in the 
family of cytochrome P450 of enzymes and the ABC family of transporters.  As such, we
wished to determine whether the ontogeny observed in ABC transporters in our rat li
could be partially explained by its regulation through the nuclear receptors.  As 
previously mentioned, HNF4α for
 
vers 
ms a higher level of regulation for drug metabolism and 
transport by acting as a master regulator of nuclear receptors PXR and CAR [76].  We 
were
 in 
ors 
 correlated with Mrp2 expression in the 
rat livers (r  = 0.83, p < 0.0001).  This suggests that regulation of hepatic Mrp2 
expre
at liver 
d 
on and 
xposures of 
se 
o 
n 
ically 
 able to describe a positive correlation between Hnf4α, Pxr, Car, and Fxr mRNA 
expression.  Although our correlation cannot establish a direct causal relationship in 
Hnf4α regulation of Pxr, Car, and Fxr, the data suggests a possible common pathway
the maturational regulation of these nuclear receptors.  Aside from the nuclear recept
themselves, we also reported a positive correlation between Pxr, Car, and Fxr with the 
ABC transporters.  In particular, Fxr was highly
2
ssion occurs mainly through Fxr with minimal co-regulation by other nuclear 
receptors. 
 
The ontogeny of the ABC transporters and the nuclear receptors from our r
samples all indicated an increase in their expression to levels comparable to adult rats 
between 14 days and 28 days of age.  This might be due to changes in environmental an
xenobiotic exposures during this phase of development.  Specifically, rat wean from 
breast milk at postnatal day 21 [99].  An increase in nuclear receptor expressi
subsequent drug transporter expression might be due to changes in dietary e
these rats. 
 
In conclusion, the findings in the current study further characterized the postnatal 
ontogeny of Mdr1/P-gp and Mrp2 during liver development in the rat.  Specifically, 
Mdr1/P-gp and Mrp2 expression are incomplete early in the postnatal period but increa
throughout maturation.  As regulatory agents of ABC transporter expression, we als
characterized the age-associated expression of nuclear receptors Pxr, Car, Fxr, and 
Hnf4α.  Again, we observed low expression of nuclear receptors a birth that increased to 
adult values with maturation.  Furthermore, we described positive correlations betwee
the expressions of the nuclear receptors and the ABC transporters.  An important 
extension of the current work will be to characterize whether changes in the expression 
Mdr1/P-gp and Mrp2 during normal pediatric development can translate into clin
significant difference in the elimination medications used in pediatric pharmacotherapy. 
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CHAPTER 4.   THE EFFECT OF MRP2 DEFICIENCY ON THE IN VIVO 
PHARMACOKINETICS OF CEFTRIAXONE IN RATS 
 
 
Introduction 
 
The human multi-drug resistance proteins (MRPs) consist of a family of ATP-
binding cassette (ABC) transporters that mediate the unidirectional transport of variou
organic anions as well as lipophilic substances conjugated to glutathiones, glucuronates, 
or sulfates.  MRP2 (ABCC2) has been recognized as a major transporter of bilirubin and 
drug substrates as well as their conjugates into the bile.  Thus, for drugs with 
considerable biliary excretion, changes in MRP2 expression may translate into profound
differences in their pharmacokinetic profile and subsequent therapeutic efficacy.
has been associated with the biliary excretion of several therapeutic agents and its 
metabolites
s 
 
 MRP2 
 used in pediatric pharmacotherapy including various antibiotics, 
chem herapeutic agents, and HIV protease inhibitors [103].  Specifically, MRP2 has 
been 
r 
t 
em as a widely used animal model for the study of Mrp2 function in drug 
disposition [97]. 
 
population for ear infections, respiratory tract infections, as well as meningitis.  In 
contrast to the aforementioned MRP2 substrates, ceftriaxone is primarily eliminated by 
renal and biliary excretion (33-67%) and does not appear to be metabolized to a relevant 
extent [50].  Additionally, ceftriaxone is excreted into the bile as an unconjugated drug 
[49, 104, 107]. Thus, studies on the effect of MRP2 ontogeny on ceftriaxone 
pharmacokinetics (PK) are not be obscured by concurrent developmental processes in 
Phase I or Phase II drug metabolizing enzymes, making ceftriaxone an ideal model drug 
to study the functional consequences of transporter maturation on in vivo 
pharmacokinetics. Additionally, there are implications that impaired MRP2 activity may 
play a role in adverse events associated with ceftriaxone used in neonates. While the 
product label advises against administering ceftriaxone to hyperbilirubinemic neonates, 
ot
implicated in the biliary excretion of several therapeutic agents and its metabolites 
used in pediatric pharmacotherapy, including irinotecan, saquinavir, ritonavir, indinavi
and ceftriaxone [104, 105].  In humans, a deficiency in MRP2 occurs in patients with 
Dubin-Johnson syndrome. Clinically, Dubin-Johnson syndrome manifests in chronic 
conjugated hyperbilirubinemia as well as impaired conjugated organic anion transpor
[106].  Mrp2 deficiency also occurs naturally in the TR-/Abcc2 strain of Wistar rats 
rendering th
 
As reported in the Chapters 2 and 3, MRP2 mRNA and protein expression in 
humans and rats are limited in the early periods of development and increase with 
maturation.  Immaturity of MRP2-mediated drug transport throughout the body, 
including decreased MRP2-mediated hepatic biliary excretion, may be a source of 
deviation in drug pharmacokinetic properties between newborns and infants as compared 
to adults.   
 
We chose the third-generation cephalosporin antibiotic ceftriaxone (Rocephin®) as
model drug to study the effect of ontogeny on MRP2-mediated elimination processes. 
Ceftriaxone is a broad spectrum cephalosporin antibiotic commonly used in the pediatric 
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several clinical reports of ceftriaxone induced cholestasis and pseudolithiasis in ne
and children exist in the literature [54, 108]. While little is known about the mecha
ich leads to the biliary sludge, particularly for the high risk ped
onates 
nism 
wh iatric population, data 
plicates the reduced biliary excretion of ceftriaxone possibly due to an immature 
RP2 in the pediatric patients [97, 109].  This suggests that newborns, particularly 
premature infants whose drug clearan  are still in development, may 
particularly be at a higher risk for ceftriaxone induced hyperbilirubinemia and 
chole
el using 
e 
vide any 
  
-
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Materials and Methods 
 
6) rats were obtained from Harlan Inc. (Indianapolis, IN).  All animals were 
catheterized in the external jugular vein by the vendor. Catheters were exteriorized 
betw
ine 
d 
 
or injection.  
 
fter 
im
M
ce mechanisms
stasis.   
 
The aim of the present study was to evaluate possible variations in ceftriaxone 
disposition due to a deficiency in Mrp2 mediated biliary excretion.  To do so, the 
pharmacokinetic parameters of ceftriaxone were determined in an animal mod
wild-type and Mrp2-deficient (TR-) rats. The TR- rat was used as a model for decreased 
hepatic Mrp2 expression as observed in neonates and young infants.  We quantified 
hepatic Mrp2 mRNA and protein levels in the WT and TR- rats in order to assess th
contribution of Mrp2 to ceftriaxone kinetics.  While the literature does not pro
evidence of Mdr1/P-gp in the biliary excretion of ceftriaxone, there is, in general, a 
certain shared degree of overlapping substrate specificity between Mdr1 and Mrp2 [103].
Therefore, we also needed to assess the potential role of P-gp in the biliary excretion of 
ceftriaxone through relative quantification of mRNA and protein expression of Mdr1/P
gp in the TR- and WT rats.  The results of this study ultimately provide information fo
better understanding of the potential for transporter mediated ceftriaxone toxicity in 
pediatric pharmacotherapy and the effect of transporter maturation in general. 
 
 
 
Pharmacokinetic Study 
 
Eight-week old male Wistar (Hsd:WI, n = 7) and Mrp2 deficient TR- (HsdAmc:TR-
Abcc2, n = 
een the shoulder blades to ensure the catheter remained in place over the sampling 
interval.  Patency of the catheter was maintained by flushing the catheter daily with sal
and heparinized glycerin solution (500 U/ml) as per vendor protocol.  All animals were 
housed in individual standard laboratory cages on a 12 hour light-dark cycle and ha
access to food and water ad lilbitum.  The experimental protocol was approved by the 
Animal Care and Use Committee (ACUC) of the University of Tennessee Health Science
Center. 
 
All animals were allowed to recover from surgery for at least two days before 
initiation of the PK study.  On the first day of the PK study, the animals were given a 
single tail vein injection of ceftriaxone 100 mg/kg reconstituted in saline f
The rats were kept in plastic metabolic cages throughout the duration of the study.  Blood
samples were collected at predose, and 5, 15, 30, 60, 90, 120, 180, 240, and 360 min a
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the dose.  Approximately 200 µL of blood was drawn from the jugular vein catheter and 
replaced immediately with an equal volume of saline solution.  Blood samples were 
stored in BD microvolume heparinized blood tubes and placed on ice.  Plasma was 
separated by centrifuging the samples for 2 minutes at 15,000 g at 4ºC.  Cumulative 
hour urine and feces were also collected.  Plasma fractions, urine, and fecal samples 
stored at -20'C until analysis.   
 
At the en
24 
were 
d of the study, all rats were anesthetized with carbon dioxide gas (CO2) 
and sacrificed by cervical dislocation.  Rat liver biopsies were dissected out and 
imme until 
l 
ntrol 
software.  
Chromatographic peak separation was performed using the Gemini™ 5-µ C18 column 
(150 x 4.6 mm) after passing through a Security Guard™ C18 4.0 x 2.0 mm guard column 
(Phenomenex, Torrance, CA).   
hemicals and Reagents 
eftriaxone sodium salt, cefuroxime sodium salt, and 
hexad
f 
Quantification 
d 
 
diately frozen in liquid nitrogen.  All frozen liver samples were stored at -70ºC 
further processing. 
 
 
Ceftriaxone Assay 
 
Equipment 
 
Ceftriaxone plasma concentrations were determined by high pressure liquid 
chromatography (HPLC). The HPLC system consisted of a Shimadzu LC system 
(Columbia, MD) which included a system controller (model SLC 10AVP), pump (mode
LC-10AD), autosampler (Prominence SIL-20A), and UV detector (SPD-10AV) set at 270 
nm and 0.01 absorbance unit.  Data acquisition, processing, reporting, and system co
were performed with the LCsolution version 1.21 (Shimadzu, Columbia, MD) 
 
C
 
C
ecyltrimethylammonium bromide (HDTA) were all purchased from Sigma-Aldrich 
(St. Louis, MO).  Potassium monophosphate (KHPO4), HPLC grade water and HPLC 
grade acetonitrile were both obtained from Fisher Scientific (Fair Lawn, NJ).   
 
The mobile phase consisted of 57-43% acetonitrile (v/v) in 10 mM K2HPO4 buffer, 
pH 7.0, with 10 mM HDTA.  A stock solution of 1 M K2HPO4 was made in distilled, 
deionized water and later added to the mobile phase to make 10 mM K2HPO4.  10 g o
HDTA was weighed out and added to 1 L of mobile phase.  The mobile phase was 
degassed with a sonicator for 15 minutes.  The flow rate was set at 1.0 mL/min.   
 
 
Quantification of ceftriaxone in rat plasma was modified from previously reporte
methods [110-113].  Plasma samples (50 µl) were deproteinated with 450 µl of ice-cold
methanol (Fisher Scientific, Fair Lawn, NJ) along with 12.5 µl of a stock 100 µg/ml 
cefuroxime solution as the internal standard.  The sample was vortexed and placed on ice 
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for 5 minutes followed by centrifugation at 2600 rpm for 5 minutes at 4ºC.  50 µl of the 
plasma supernatant was used for HPLC analysis. 
 
Rat urine samples were diluted ten fold by adding to 100 µl of urine 900 µl of 
HPLC grade water along with 25 µl of the stock solution of cefuroxime 100 µg/ml.  The 
samples were then vortexed and centrifuged at 2600 rpm for 5 minutes at 4ºC.  25 µl of 
the resu
amples 
0 µl of HPLC grade water along with 25 µl of the internal standard 
ock solution.  The mixture was vortexed and 25 µl was used for HPLC analysis. 
e was constructed by calculating the peak area ratio of ceftriaxone 
nal standard cefuroxime for each of a series of calibration standards.  The 
n of calibration standards of ceftriaxone ranged from 10 through 500 µg/ml 
for pl peak 
 
is 
zed by noncompartmental 
), 
1/2
urine
 
tein Quantification for Mdr1a/1b and Mrp2  
 
 
lting supernatant was then used for HPLC analysis.  
 
Rat fecal samples were first homogenized in 10 ml of distilled water.  The s
were then centrifuged at 2600 rpm for 5 minutes at 4ºC.  100 µl of the supernatant was 
hen diluted with 90t
st
 
A standard curv
and the inter
conce tration
asma, 10 through 800 µg/ml for urine, and 0.5 through 5 g/ml for feces.  The 
area ratio of the standards was plotted against their concentrations, and ceftriaxone
concentration from the experimental samples was calculated by linear regression from the 
corresponding standard curves.  All calibration curves were made prior to measurement 
of the experiment samples with correlation values of at least 0.995.  The lower limit of 
quantification (LLOQ) was 10 µg/ml for plasma and urine and 500 µg/ml for fecal 
samples.  The accuracy of the assay was 13% and 17% at the LLOQ while the precision 
was 15%.. 
 
 
Pharmacokinetic Analys
 
The concentration-time data for ceftriaxone were analy
pharmacokinetics analysis using WinNonlin Professional version 4.1 (Pharsight 
Corporation; Mountain View, CA).  Pharmacokinetic parameters calculated include 
clearance (CL), volume of distribution at steady state (Vss), area under the curve (AUC
elimination rate constant (k), half life (t ), percent dose of unchanged drug detected in 
 (% urine), and percent dose of unchanged drug detected in feces (% fecal).  
Statistical analyses comparing each pharmacokinetic parameter between the TR- rats and 
wild-type Wistar rats was performed using a two-tailed unpaired Student’s t-test through
SPSS version 14.0 (Chicago, IL).   
 
 
mRNA and Pro
 
Mdr1a/1b and Mrp2 mRNA and protein levels from the frozen rat liver tissues were
analyzed using real time RT-PCR for mRNA quantification and Western immunoblotting
for protein quantification. 
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Briefly, approximately 0.3 g of frozen liver tissue was added to 600 µl of 
denaturing solution and homogenized using a handheld homogenizer for approximately 
15 seconds or until no fragments of tissue were visible. Total RNA from the rat livers 
was i
, 
uantitative PCR was 
performed on an ABI Prism 7000 Sequence Detection System (Applied Biosystems, 
Foste  
 
 
 
e 
 
d in 5% nonfat dried milk in PBST for two hours.  After discarding the 
rimary antibody, the membrane was washed by three separate five minute washes with 
hen incubated for one hour with the secondary antibody, 
 IgG (Cell Signaling Technology, Danvers, MA), diluted in 
5% n
ce 
Results 
1.  The concentration-time curve appears monoexponential for 
both groups.  Mean pharmacokinetic parameters for ceftriaxone in wild-type and TR- rats  
solated using RNAgents® Total RNA Isolation Kit (Promega, Madison, WI) 
according to the manufacturer’s protocol.  First strand cDNA was synthesized from total 
liver RNA using the SuperScript™ III First Strand cDNA Synthesis (Invitrogen, Carlsbad
CA) according to the manufacturer's instructions. Real-time q
r City, CA) using primer pairs and TaqMan probes for rat Mdr1a, Mdr1b, and Mrp2
as well as the reference gene cyclophilin (see Chapter 3 for discussion on reference gene
selection).  Relative mRNA quantification was achieved using a relative standard curve 
methodology. 
 
Protein levels of Mrp2 in the rat liver tissues were quantified through Western blot 
analysis.  Approximately 0.5 g of rat liver tissue was used for membrane protein isolation
through the use of Calbiochem® ProteoExtract® Native Membrane Protein Extraction Kit
(M-PEK) according to the manufacturer’s protocol.  20 µg of rat liver membrane protein 
was fractionated using SDS-PAGE technique with NuPAGE® 4 – 12 % Bis-Tris Gel.  
The separated proteins were then transferred overnight onto a Invitrolon™ PVDF 0.2 µm 
membrane.  Nonspecific binding sites on the PVDF membrane were blocked using 5% 
nonfat dried milk in phosphate buffered saline (pH 7.4) with 0.1% Tween (PBST) for on
hour followed by primary monoclonal antibody incubation with P-gp (C219) (Alexis 
Biochemicals, San Diego, CA) diluted 1:100 fold, MRP2 (M2III-6) (Alexis Biochemical,
San Diego, CA) diluted 1:200 fold, or GAPDH (Sigma-Aldrich, St. Louis, MO) diluted 
:10000 fol1
p
PBST.  The membrane was t
HRP- onjugated Anti-Mousec
onfat dried milk in PBST either 1:5000 fold when probing P-gp and MRP2, or 
1:10000 fold when probing for GAPDH.  After another three separate five minute 
washings with PBST, the blots were then incubated with enhanced chemiluminescen
ECL plus™ (GE Healthcare, Piscataway, NJ) for 5 minutes, then developed on Kodak 
Biomax XAR autoradiography film after 1 minute and 3 minute exposure times.  Protein 
band density was quantified using ImageJ (National Institutes of Health) after digitizing 
the image using a flatbed scanner. 
 
 
 
 
Ceftriaxone Pharmacokinetics 
 
The mean plasma concentration versus time profile following a single intravenous 
injection of ceftriaxone 100 mg/kg in wild-type (WT) and Mrp2-deficient (TR-) Wistar 
rats is depicted in Figure 4- 
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Figure 4-1. Plasma Ceftriaxone Concentration versus Time Profile in WT versus TR-
Rats. 
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are summarized in Table 4-1.  The area under the curve (AUC) of ceftriaxone in TR- rats 
was approximately 30% higher than in WT rats.  This may be attributed to the 30% 
decrease in clearance in the TR- rats.  The elimination rate constant (k) decreased by 
37%; consequently, terminal half-life (t1/2) of ceftriaxone in plasma was significantly 
prolonged by approximately 34%.  The volume of distribution at steady state (Vss) was 
not significantly different between the two groups.  The percent dose of ceftriaxone 
eliminated in the urine was significantly increased from 25.5% to 64.5% in TR- rats as 
compared to controls (p < 0.001).  Conversely, the percent dose of ceftriaxone recovered 
in feces was significantly higher in control rats than TR- rats (18.5% vs. 0%; p < 0.05). 
 
 
Mdr1a, Mdr1b, and Mrp2 mRNA and Protein Quantification 
 
We were able to detect Mdr1a, Mdr1b, and Mrp2 mRNA using real-time PCR in all 
WT and TR- rat liver samples.  Significant differences were detected for all three mean 
target gene expression between WT and TR- rats.  TR- rats livers exhibited 
approximately three-fold higher expression of Mdr1a (p < 0.001) and Mdr1b (p < 0.05) 
as compared to WT rat liver samples.  As expected, TR- rat liver samples contained 
limited levels of Mrp2 mRNA, which was significantly lower than WT Mrp2 expression 
levels (p < 0.05) (Figure 4-2).  Western blot analysis of WT and TR- rats revealed a 
single band at ~170 kDa corresponding to Mdr1/P-gp as well as at ~190 kDa 
t liver tissues (Figure 4-3).  Mean normalized protein 
ve
 
s compared to WT rat liver (p < 0.05) (Figure 4-4)  Removal of outliers defined as 
samples with relative expression values 1.5 times outside the 25th and 75th percentiles had 
no influence on the statistical results. 
 
 
Discussion 
 
The present pharmacokinetic study on ceftriaxone disposition in WT vs. TR- rats 
clearly demonstrates the significance of Mrp2 mediated biliary excretion of ceftriaxone.  
Judging from the plasma concentration-time profile of a single intravenous administration 
of ceftriaxone in WT and TR- rats, we observed a significantly lower elimination rate 
constant (k) for TR- rats as compared to the WT rats.    We could attribute the change in 
elimination rate constant as an overall decrease in clearance in the TR- rats since there 
were no changes in volume of distribution between the two groups.  This translated into a 
higher systemic exposure/AUC of ceftriaxone in the TR- rats.  Since ceftriaxone is nearly 
completely eliminated as unchanged drug by excretion into the bile and urine, we were 
able to delineate the contribution of renal versus biliary elimination without any 
confounding effects of drug metabolizing enzymes.   
 
No detectable amounts of ceftriaxone (LLOQ of 500 µg/ml in feces) were detected 
in the TR- fecal samples after 24 hours.  However, approximately 19% of the original 
corresponding to Mrp2 in the ra
expression le ls were not significantly different for Mdr1/P-gp between WT and TR- 
rats.  However, mean Mrp2 protein expression level was significantly reduced for TR- rat
liver a
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Table 4-1. Mean ± SD Pharmacokinetic Parameters in WT versus TR- Rats. 
 
   
 Wild-type TR- 
   
   
k (h-1) 0.928 ± 0.24 0.588 ± 0.06b
t1/2 (h) 0.788 ± 0.19 1.19 ± 0.12c
Vss (L/kg) 0.321 ± 0.11 0.314 ± 0.05 
L  (L/h/kg) 0.279 ± 0.09 0.189 ± 0.05a
123 ± 0.05b
AUC (mg*h/L) 396 ± 148 570 ±182 
% uri
C T
CLr (L/h/kg) 0.076 ± 0.05 0.
inf 
ne (24 h) 25.5 ± 12 64.5 ± 17
% fecal (24 h) 18.5 ± 16 0.0 ± 0.0
   
c
a
a p < 0.05; p < 0.01; p < 0.001 
 
 
b c 
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Figure 4-2  WT versus TR- Rat Liver Mdr1a, Mdr1b, and Mrp2 mRNA Expression. 
Bar graph presenting mean ± standard deviation for hepatic mRNA gene expression of 
Mdr1a, Mdr1b and Mrp2 (normalized for cyclophilin (Cyc) expression) in WT vs. TR- 
rats. Asterisks (*) represent a significant difference (*p < 0.05; **p < 0.001). 
 
 
*
WT TR- control
P-gp (~170 kDa)
Mrp2 (~190 kDa)
 
 
Figure 4-3. Immunoblot of WT and TR- Rat Liver P-gp and Mrp2 Protein  
Expression. 
Representative Western blots of P-gp and Mrp2 in wild-type (WT) and Mrp2-deficient 
rats (TR-).  P-gp and Mrp2 control membranes were included in each blot as a reference.
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WT and TR- rats. Lower panel: Bar graph presenting mean ± standard deviation for 
normalized P-gp and Mrp2 mRNA gene expression in WT vs. TR- rats. 
 
 
Figure 4-4. WT versus TR- Mdr1/P-gp and Mrp2 Protein Expression. 
Upper panel: Scatterplot of normalized P-gp and Mrp2 protein expression of individual 
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dose of ceftriaxone was recovered in the 24 hour fecal samples of the WT rats.  This 
supports our hypothesis that biliary excretion of ceftriaxone is mediated through liver 
Mrp2.  This is further supported by the mRNA and protein quantification of Mdr1a/b and 
Mrp2 in both the WT and TR- rats.  Biliary excretion of ceftriaxone through Mdr1/P-gp 
is improbable since expression of P-gp was detected in TR- rats yet no detectable amount 
of ceftriaxone was recovered from the feces.   
 
Our results showed an apparent increase in renal clearance of ceftriaxone in the TR- 
rats as compared to the WT rats.  This may indicate a potential compensatory mechanism 
in the TR- rats for the overall clearance of ceftriaxone.  Rat glomerular filtration rate has 
been estimated at 0.312 L/h/kg [114].  The predicted filtration rate of ceftriaxone in WT 
rats with a unbound fraction estimated at 5% would therefore be 0.0156 L/hr/kg [113].  
Ceftriaxone renal elimination in both the WT and TR- rats appeared to undergo a net 
filtration and secretion process since the excretion ratio exceeded one in both instances.  
Previous reports have also demonstrated an increase in the urinary excretion of various 
organic anions with Mrp2-deficient rats [115, 116].  This indicates a potential up-
regulation of other drug transporters in the kidney to compensate for the loss of Mrp2 
function.  Chen et al. [67] have recently provided evidence of increased Mrp4 expression 
in the kidneys of TR- rats.  Given that Mrp2 and Mrp4 share overlapping substrate 
profiles as well as similar co-localization at the apical membrane of renal proximal 
tubules, the increase in renal clearance may be attributed to the upregulation of renal 
Mrp4 in the TR- rats.  However, further experiments in TR- rats would be needed in 
order to confirm the underlying mechanisms which contribute to the renal elimination of 
ceftriaxone.   
 
One other finding of interest was the significant elevation in mRNA expression 
level of Mdr1a and Mdr1b in the TR- rats as compared to the WT rats.  However, the 
protein level of P-gp in the TR- rats was not significantly different from the WT rats.  
The discordance in Mdr1a/b mRNA and P-gp protein expression suggests potential 
regulatory mechanisms at the post-transcriptional level. 
 
Mrp2 mediated biliary excretion has potentially important clinical implications for 
pediatric pharmacotherapy.  As concluded in the previous chapters, newborn and young 
infants have decreased or immature expression of hepatic Mrp2 as compared to older 
children and adults.  For drugs with significant elimination through the bile, such as 
ceftriaxone, competition for biliary excretion via Mrp2 especially in the early stages of 
development may exacerbate or even cause clinical symptoms such as hyperbilirubinemia 
or even cholestasis.  Reduced MRP2 mediated biliary excretion may also translate to a 
bstantially decreased clearance and prolonged half-life of the affected medications in 
reasing the 
II metabolism, 
e impact of the ontogeny of Phase III drug transporters must be considered when 
determining the pharmacokinetic profile of the drug or its metabolites.  For example, for 
a compound that is biotransformed into a glucuronidated or sulfated metabolite which is a 
su
neonates and infants with immature biliary excretion function, thereby inc
systemic exposure to these compounds.  For drugs with a narrow therapeutic window, 
decreased Mrp2 mediated biliary excretion may lead to toxic drug concentrations in 
newborns and infants.  Even for drugs which undergo Phase I and Phase 
th
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substrate for Mrp2, the potential competition for Mrp2 mediated biliary elimination m
result in significant metabolite accumulation and subsequent reduced metabolic 
conversion of the parent drug and/or undesirable side effects related to the increased 
concentrations of parent drug or the metabolite. 
 
The present study clearly defines the changes in pharm
ay 
acokinetic parameters for 
ceftriaxone in wild-type versus Mrp2-deficient TR- rats.  We use this animal model to 
illust
h 
  
rate the impact of low or deficient Mrp2 expression on drug elimination especially 
during the early stages of pediatric development as profiled in the human liver samples of 
newborns and infants investigated in Chapter 2.  Pediatric clinical trials studying these 
effects are often unfeasible due to limitations in cost, recruitment, biological sampling, 
and ethical issues.  The utility of mutant or knock-out animal models is invaluable in suc
cases where human studies are not feasible.  While inter-species differences must be 
considered when extrapolating results from animal models to humans, an understanding 
of the basic effects of drug transporters and lack of their functional activity on in vivo 
drug pharmacokinetics nevertheless brings us a step closer to understanding and 
explaining some of the variability and toxicity observed in pediatric pharmacotherapy. 
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CHAPTER 5.   SUMMARY 
 
 
Advances in technology and understanding of systems biology have provided 
treme  
le 
ng 
 
In order to map out  the ontogeny of these transporters in more detail, we also measured 
their expression in rats from seven specific ages ranging from newborn to adult.  In 
addition, we sought to explain their potential developmental pattern by examining the 
expression of their regulators in the superfamily of nuclear receptors – including PXR, 
CAR, FXR, and HNF4α.  Lastly, we demonstrated the potential clinical impact of 
maturational changes in drug transporters on the pharmacokinetic properties of 
ceftriaxone, a third generation cephalosporin antibiotic often used in the pediatric 
population. 
 
Our study in human pediatric liver samples revealed significantly lower MDR1/P-
gp mRNA expression between the early infant (before 8 months) and older childhood 
period.  Our MDR1/P-gp protein expression in the pediatric liver samples, however, did 
not support the results for MDR1 mRNA expression.  P-gp protein level was not 
significantly different across the various age groups in our subset of protein samples.  
The discordance in the relative expression of MDR1/P-gp mRNA and P-glycoprotein has 
been described in various cancer cell lines [81, 82].  This raises the possibility of post-
transcriptional regulation of MDR1 as a potential source of variation for mRNA and 
protein expression in human pediatric liver samples. 
 
MRP2 mRNA and protein quantification in the human pediatric liver samples 
revealed significant differences during ontogeny.  Specifically, we demonstrated that 
MRP2 expression is limited in the early infant period but increases dramatically to levels 
comparable to childhood levels immediately prior to one year of age.  Clinically, 
newborns are often jaundiced in the early postnatal period.  This is thought to partly be 
due to the relatively immature hepatic metabolic pathways and hepatic transporter 
mediated elimination of unconjugated bilirubin.  MRP2 is the primary hepatic canalicular 
transporter that mediates various organic anions as well as sulfated or glucuronidated bile 
salts and bilirubin.  We provide evidence that hepatic expression of MRP2 is immature at 
birth, and therefore, drugs with high biliary excretion may exhibit altered 
pharmacokinetic properties and should be administered with caution in newborns. 
ndous strides towards improvements in modern human medicine.  Unfortunately,
the business of drug development often overlooks the needs of the pediatric population 
mainly due to cost issues as well as a lack of understanding of the dynamic changes 
which occur in children especially in the early stages of their development.  Therefore, as 
more and more studies emerge on human organogenesis and physiology, it is the 
responsibility of clinical pharmacologists to translate such knowledge into safe and 
effective pharmacotherapy for all ages.  In the current dissertation, we hypothesized that 
there are age associated changes in drug transporter expression which can lead to 
significant changes in pharmacokinetic parameters of drugs often used in pediatric 
pharmacotherapy.  We aimed at unraveling a piece of the childhood development puzz
through characterization of the ontogeny of two major members in the ATP-bindi
cassette (ABC) family of drug transporters – MDR1/P-gp and MRP2 in human samples. 
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Nuclear receptors belon
expression of their target genes
g to a family of transcriptional factor which regulate the 
, several of which include drug metabolizing enzymes and 
ansporters.  In particular, several nuclear receptors including PXR, CAR, FXR, and 
NF4α have been identified as regulatory agents for ABC transporters including 
MDR1 r 
 
tected 
bile 
 
n 
lated 
ited 
eriods of development, but gradually increased to maximal expression levels 
at approximately 28 days of age.  Results for 
ion 
 our 
ansporter expression could result in 
significant changes in the pharm
 
ry 
tr
H
/P-gp and MRP2.  We quantified the expression of the nuclear receptors in orde
to establish their regulatory role in the development of MDR1/P-gp and MRP2.  Our 
results revealed an interesting profile.  PXR and FXR exhibited a lower expression level
in the early phase of development.  However, CAR and HNF4α showed no differences 
throughout the early postnatal through childhood ages.  Though both PXR and FXR 
expression was lower in the earlier age group, significant differences were only de
for FXR.  Physiogically, this makes plausible sense since FXR is often referred to as a 
bile sensor capable of regulating the molecular processes which maintain bile acid 
homeostasis.  Immaturity of FXR expression at birth is supported by evidence that 
acid synthesis and homeostasis appear to be postnatal ontogenic events as well. 
 
Due to the limitations of conducting scientific research in humans, the use of 
animal models has historically provided great insight into our understanding of human 
development.  As such, we wished to examine the ontogeny of Mdr1a/1b, Mrp2, Pxr, 
Car, Fxr, and Hnf4α from rat liver samples in seven different postnatal ages in order to
compliment our human results with more selected spacing of age and sample numbers i
our rat samples.  While the age at which maximal expression of these transporters and 
nuclear receptors differed; in general, we observed a developmental pattern in the 
expression of all the target genes.  The protein levels for P-gp and Mrp2 also corre
well with the mRNA expression data.  Expression of Mdr1/P-gp and Mrp2 were lim
in the early p
the nuclear receptors Pxr, Car, and Fxr were 
similar in that rat livers from 0 to 21 postnatal days initially exhibited less than 50% of 
adult rat liver content but increased dramatically from 28 days of age to adulthood.  A 
similar pattern was observed for Hnf4α, though its mean relative expression appeared 
highly variable within each age group.  From the rat model, we concluded that express
of Mdr1a/1b, Mrp2, Pxr, Car, and Fxr, in rat liver samples were significantly lower in the 
early postnatal period as compared to the older age groups. 
 
The results from the human and rat liver transporter ontogeny studies led us to
next hypothesis that developmental changes in drug tr
acokinetic parameters of drug substrates for these 
transporters.   We decided to test our hypothesis by comparing the pharmacokinetic 
parameters of ceftriaxone, a third generation cephalosporin antibiotic, in wild-type (WT) 
and a mutant strain of Mrp2-deficient (TR-) rats.  We selected Mrp2-deficient rat as a 
surrogate model to represent the immaturity of Mrp2 early on in development as was 
evident from our rat and human liver samples.  Ceftriaxone clearance was approximately
30% lower in the TR- group as compared to the WT group.  Elimination half-life was 
approximately 30% longer for the TR- group since there was no significant change in 
volume at steady state between the two groups.  There were no recoverable amounts of 
ceftriaxone in the feces of TR- rats as compared with the 19% unchanged drug recovered 
in the feces of the WT rats.  Interestingly, there was almost a 40% increase in urina
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excretio
ges 
n 
y 
ill lie in 
the translation of our knowledge of the developmental pharmacology and biology during 
childho
n of ceftriaxone in the TR- indicating a potential compensatory mechanism for 
clearance of the drug.  mRNA and protein expression of Mdr1a/1b and Mrp2 confirmed a 
deficiency of Mrp2 in the TR- rats as well as confirming the biliary excretion of 
ceftriaxone by Mrp2. 
 
We have successfully determined the age associated expression of ABC 
transporters MDR1/Mdr1a/b and MRP2/Mrp2 in both human and rat liver samples.  
Furthermore, we also examined developmental expression of various nuclear receptors 
thought to be regulators of these drug transporters.  Lastly, we demonstrated the chan
in pharmacokinetic properties of ceftriaxone in a Mrp2-deficient rat model.  The results 
of this study not only emphasize that children are not small adults, i.e. have distinctly 
different drug disposition mechanisms, but also that empiric dosing of drugs based o
adult pharmacotherapy often used in the pediatric population may compromise the safet
and efficacy of these medications.  The challenge in pediatric pharmacotherapy w
od into rational and practical drug design as well as age-appropriate dosing 
recommendations.
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